{"content":"<li class=\"n-box-item date-title\" data-end=\"1555387199\" data-start=\"1555300800\" data-txt=\"Monday, December 23, 2019\">Monday, April 15, 2019</li><li class=\"n-box-item sa-box-item\" data-id=\"3450892\" data-ts=\"1555364548\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/BRS\" target=\"_blank\">BRS</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3450892-bristow-to-skip-interest-payment-explores-options\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Bristow to skip interest payment as it explores options</a></h4><ul><li>Bristow (NYSE:<a href='https://seekingalpha.com/symbol/BRS' title='Bristow Group Inc.'>BRS</a>) <font color=\"red\">-39.2%</font> after-hours as it says it <a href=\"https://seekingalpha.com/pr/17477099-bristow-provides-financial-update\" target=\"_blank\">will not make a ~$12.5M interest payment</a> due April 15 on its 6.25% senior notes maturing in 2022.</li><li>BRS says it will use the 30-day grace period to continue working with its advisors and creditors to review alternatives for improving its capital structure.</li><li>The company also has obtained waivers from lenders that extend the  deadline for filing its Form 10-Q for the quarter ended Dec. 31, 2018 to June 19,  2019.</li></ul><div class=\"tiny-share-widget\" data-id=\"3450892\" data-linked=\"Bristow to skip interest payment as it explores options\" data-tweet=\"$BRS - Bristow to skip interest payment as it explores options https://seekingalpha.com/news/3450892-bristow-to-skip-interest-payment-explores-options?source=tweet\" data-url=\"https://seekingalpha.com/news/3450892-bristow-to-skip-interest-payment-explores-options\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  5:42 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>18&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3450887\" data-ts=\"1555364037\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/\" target=\"_blank\"></a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3450887-after-hours-gainers-losers\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">After Hours Gainers / Losers</a></h4><ul><li><strong>Gainers: </strong><a href='https://seekingalpha.com/symbol/CHMA' title='Chiasma, Inc.'>CHMA</a> <font color=\"green\">+4.3%</font>. <a href='https://seekingalpha.com/symbol/JMIA' title='Jumia Technologies AG'>JMIA</a> <font color=\"green\">+2.5%</font>. <a href='https://seekingalpha.com/symbol/PCB' title='Pacific City Financial Corporation'>PCB</a> <font color=\"green\">+2.1%</font>. <a href='https://seekingalpha.com/symbol/FTEK' title='Fuel Tech, Inc.'>FTEK</a> <font color=\"green\">+1.9%</font>.</li><li><strong>Losers: </strong><a href='https://seekingalpha.com/symbol/JBHT' title='J.B. Hunt Transport Services, Inc.'>JBHT</a> <font color=\"red\">-3.8%</font>. <a href='https://seekingalpha.com/symbol/ATAI' title='ATA Inc.'>ATAI</a> <font color=\"red\">-2.1%</font>. <a href='https://seekingalpha.com/symbol/RCKT' title='Rocket Pharmaceuticals, Inc.'>RCKT</a> <font color=\"red\">-2.1%</font>. <a href='https://seekingalpha.com/symbol/CIG' title='Companhia Energética de Minas Gerais'>CIG</a> <font color=\"red\">-0.8%</font>.</li></ul><div class=\"tiny-share-widget\" data-id=\"3450887\" data-linked=\"After Hours Gainers / Losers\" data-tweet=\"$CHMA $JMIA $PCB - After Hours Gainers / Losers https://seekingalpha.com/news/3450887-after-hours-gainers-losers?source=tweet\" data-url=\"https://seekingalpha.com/news/3450887-after-hours-gainers-losers\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  5:33 PM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3450867\" data-ts=\"1555361935\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/GOGO\" target=\"_blank\">GOGO</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3450867-gogo-closes-up-8_1-analysts-parse-early-results-refinancing\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Gogo closes up 8.1% as analysts parse early results, refinancing</a></h4><ul>   <li>Gogo (NASDAQ:<a href='https://seekingalpha.com/symbol/GOGO' title='Gogo Inc.'>GOGO</a>) finished <font color=\"green\">up 8.1%</font> today but rose as high as a <font color=\"green\">20% gain</font>, what would have been its best day in months, after announcing its <a href=\"https://seekingalpha.com/news/3450564-gogo-announces-prelim-q1-900m-note-offering\" target=\"_blank\">preliminary results</a> and $900M refinancing.</li><li>Shares are <font color=\"green\">up another 3.5%</font> after hours.</li>    <li>That move up on more than triple average volume shows investor confidence that its transactions will be successful, Cowen notes.</li>    <li>\u201cWith strong earnings and favorable high yield market conditions, this morning\u2019s rally in Gogo shares is justified,\" says the firm's Lance Vitanza. A bit more subdued is Raymond James' Ric Prentiss, who expects \"continued turbulence over the next several quarters\u201d with convertible debt due in Q1 2020 still to address. The company also faces headwinds from American Airlines de-installations, he says. (h/t Bloomberg)</li>    <li>Both analysts rate the stock Market Perform.</li> </ul><div class=\"tiny-share-widget\" data-id=\"3450867\" data-linked=\"Gogo closes up 8.1% as analysts parse early results, refinancing\" data-tweet=\"$GOGO - Gogo closes up 8.1% as analysts parse early results, refinancing https://seekingalpha.com/news/3450867-gogo-closes-up-8_1-analysts-parse-early-results-refinancing?source=tweet\" data-url=\"https://seekingalpha.com/news/3450867-gogo-closes-up-8_1-analysts-parse-early-results-refinancing\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  4:58 PM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3450860\" data-ts=\"1555360984\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/PRTO\" target=\"_blank\">PRTO</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3450860-proteon-to-explore-strategic-alternatives-shares-up-8-after-hours\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Proteon to explore strategic alternatives; shares up 8% after hours</a></h4><ul><li>Aimed at boosting shareholder value, Proteon Therapeutics (NASDAQ:<a href='https://seekingalpha.com/symbol/PRTO' title='Proteon Therapeutics, Inc.'>PRTO</a>) will explore <a href=\"https://seekingalpha.com/pr/17477081-proteon-therapeutics-announces-review-potential-strategic-transactions\" target=\"_blank\">strategic alternatives</a> that could include an acquisition, merger or business combination.</li><li>H.C. Wainwright is advising.</li><li>Shares are up <font color=\"green\">8%</font> after hours.</li></ul><div class=\"tiny-share-widget\" data-id=\"3450860\" data-linked=\"Proteon to explore strategic alternatives; shares up 8% after hours\" data-tweet=\"$PRTO - Proteon to explore strategic alternatives; shares up 8% after hours https://seekingalpha.com/news/3450860-proteon-to-explore-strategic-alternatives-shares-up-8-after-hours?source=tweet\" data-url=\"https://seekingalpha.com/news/3450860-proteon-to-explore-strategic-alternatives-shares-up-8-after-hours\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  4:43 PM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3450859\" data-ts=\"1555360793\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/BPMX\" target=\"_blank\">BPMX</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3450859-biopharmx-down-15-after-hours-on-1-25-reverse-stock-split\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">BioPharmX down 15% after hours on 1:25 reverse stock split</a></h4><ul><li>Aimed at regaining compliance with NYSE American listing requirements, BioPharmX (NYSEMKT:<a href='https://seekingalpha.com/symbol/BPMX' title='BioPharmX Corporation'>BPMX</a>) will <a href=\"https://seekingalpha.com/pr/17477023-biopharmx-announces-reverse-stock-split\" target=\"_blank\">execute </a>a 1:25 reverse split of its common stock on April 25. Post-split trading will commence on April 26.</li><li>Shares are down <font color=\"red\">15%</font> after hours.</li></ul><div class=\"tiny-share-widget\" data-id=\"3450859\" data-linked=\"BioPharmX down 15% after hours on 1:25 reverse stock split\" data-tweet=\"$BPMX - BioPharmX down 15% after hours on 1:25 reverse stock split https://seekingalpha.com/news/3450859-biopharmx-down-15-after-hours-on-1-25-reverse-stock-split?source=tweet\" data-url=\"https://seekingalpha.com/news/3450859-biopharmx-down-15-after-hours-on-1-25-reverse-stock-split\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  4:39 PM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3450827\" data-ts=\"1555359237\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/WHR\" target=\"_blank\">WHR</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3450827-weak-shipments-data-send-whirlpool-lower\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Weak shipments data send Whirlpool lower</a></h4><ul><li>Shares of Whirlpool (NYSE:<a href='https://seekingalpha.com/symbol/WHR' title='Whirlpool Corporation'>WHR</a>) <font color=\"red\">peeled off 2.51%</font> after industry data came in weak earlier today.</li><li>The Association of Home Appliance Manufacturers reported shipments fell <a href=\"https://www.aham.org/AHAM/\" target=\"_blank\">6%</a> in March, with declines recorded across nearly every category.</li></ul><div class=\"tiny-share-widget\" data-id=\"3450827\" data-linked=\"Weak shipments data send Whirlpool lower\" data-tweet=\"$WHR - Weak shipments data send Whirlpool lower https://seekingalpha.com/news/3450827-weak-shipments-data-send-whirlpool-lower?source=tweet\" data-url=\"https://seekingalpha.com/news/3450827-weak-shipments-data-send-whirlpool-lower\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  4:13 PM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3450818\" data-ts=\"1555358913\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/JBHT\" target=\"_blank\">JBHT</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3450818-j-b-hunt-transportminus-5-after-earnings-miss\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">J.B. Hunt Transport -5% after earnings miss</a></h4><ul><li>J.B Hunt Transport Services (NASDAQ:<a href='https://seekingalpha.com/symbol/JBHT' title='J.B. Hunt Transport Services, Inc.'>JBHT</a>) reports operating revenue rose 7% Y/Y in <a href=\"https://seekingalpha.com/pr/17476938-j-b-hunt-transport-services-inc-reports-revenues-earnings-first-quarter-2019\" target=\"_blank\">Q1</a> to $2.09B. After backing out fuel surcharges, revenue was up 8%.</li><li>In the intermodal segment, revenue per load excluding fuel surcharges increased approximately 11%, partially offset by a 7% decline in volumes.</li><li>Dedicated contract services segment revenue increased by 22%, due chiefly to additional customer contracts from a year ago and customer rate increases.</li><li>Integrated capacity solutions load growth was 15%, partially offset by a 12% decrease in revenue per load over the same period in 2018.</li><li>Truck segment revenue jumped 10% during the quarter.</li><li>Operating income was $168M vs. $169M a year ago.</li><li>JBHT <font color=\"red\">-4.64%</font> AH.</li><li>Previously: <a href=\"https://seekingalpha.com/news/3450809-j-b-hunt-transport-services-misses-0_16-misses-revenue\" target=\"_blank\">J.B. Hunt Transport Services misses by $0.16, misses on revenue</a> (April 15)</li></ul><div class=\"tiny-share-widget\" data-id=\"3450818\" data-linked=\"J.B. Hunt Transport -5% after earnings miss\" data-tweet=\"$JBHT - J.B. Hunt Transport -5% after earnings miss https://seekingalpha.com/news/3450818-j-b-hunt-transportminus-5-after-earnings-miss?source=tweet\" data-url=\"https://seekingalpha.com/news/3450818-j-b-hunt-transportminus-5-after-earnings-miss\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  4:08 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>5&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3450815\" data-ts=\"1555358855\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/AUTL\" target=\"_blank\">AUTL</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3450815-autolus-nets-109m-in-equity-offering-shares-up-6-after-hours\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Autolus nets $109M in equity offering; shares up 6% after hours</a></h4><ul><li>Autolus Therapeutics (NASDAQ:<a href='https://seekingalpha.com/symbol/AUTL' title='Autolus Therapeutics plc'>AUTL</a>) is up <font color=\"green\">6%</font> after hours after it <a href=\"https://seekingalpha.com/pr/17476953-autolus-announces-closing-public-offering-full-exercise-underwriters-option-purchase\" target=\"_blank\">announced</a> the closing of its public offering of ~4.8M ADSs at $24 per ADS. Net proceeds were $109M.</li></ul><div class=\"tiny-share-widget\" data-id=\"3450815\" data-linked=\"Autolus nets $109M in equity offering; shares up 6% after hours\" data-tweet=\"$AUTL - Autolus nets $109M in equity offering; shares up 6% after hours https://seekingalpha.com/news/3450815-autolus-nets-109m-in-equity-offering-shares-up-6-after-hours?source=tweet\" data-url=\"https://seekingalpha.com/news/3450815-autolus-nets-109m-in-equity-offering-shares-up-6-after-hours\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  4:07 PM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3450814\" data-ts=\"1555358815\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/\" target=\"_blank\"></a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3450814-cryptos-fall-after-report-on-flash-boys-crypto-trading-bots\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Cryptos fall after report on`Flash Boys&#39; crypto trading bots</a></h4><ul><li>Four of the five top cryptocurrencies by market cap slide after Bloomberg publishes an article about <a href=\"https://www.bloomberg.com/news/articles/2019-04-15/-flash-boys-trading-bots-are-running-wild-on-crypto-exchanges?srnd=premium\" target=\"_blank\">a research paper</a> describing \"Flash Boys\"-like trading manipulation on certain crypto exchanges.</li><li>Bitcoin (<a href='https://seekingalpha.com/symbol/BTC-USD' title='Bitcoin USD'>BTC-USD</a>) <font color=\"red\">falls 2.5%</font> to $5,035.28; Ripple (<a href='https://seekingalpha.com/symbol/XRP-USD' title='XRP USD'>XRP-USD</a>) <font color=\"red\">-3.9% </font>to $0.3173; Ethereum (<a href='https://seekingalpha.com/symbol/ETH-USD' title='Ethereum USD'>ETH-USD</a>) <font color=\"red\">-5.5%</font> to $159.45; and Litecoin (<a href='https://seekingalpha.com/symbol/LTC-USD' title='Litecoin USD'>LTC-USD</a>)<font color=\"red\"> -8.4%</font> to $76.92.</li><li>Autonomous trading programs, or arbitrage bots, anticipate and profit from ordinary users' trades on decentralized exchanges, which let them trade more directly, according to researchers at Cornell Tech and several other universities.</li><li>The firms using the bots access priority ordering by paying higher fees; one way they profit is by front-running--monitor orders of other traders then manage to place them first.</li><li>Decentralized exchanges--or DEXes--account for only a small percentage of overall crypto trading volume, but that can increase quickly as companies like Binance build their own DEXes.</li><li>Similar practices may be occurring on centralized crypto exchanges, too, says Ari Juels, a professor at Cornell Tech.</li><li>Previously: <a href=\"https://seekingalpha.com/news/3448217-crypto-rally-continues\" target=\"_blank\">Crypto rally continues</a> (April 3)</li></ul><div class=\"tiny-share-widget\" data-id=\"3450814\" data-linked=\"Cryptos fall after report on`Flash Boys&#39; crypto trading bots\" data-tweet=\"$BTC-USD $XRP-USD $ETH-USD - Cryptos fall after report on`Flash Boys&#39; crypto trading bots https://seekingalpha.com/news/3450814-cryptos-fall-after-report-on-flash-boys-crypto-trading-bots?source=tweet\" data-url=\"https://seekingalpha.com/news/3450814-cryptos-fall-after-report-on-flash-boys-crypto-trading-bots\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  4:06 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>25&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3450811\" data-ts=\"1555358695\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/RCKT\" target=\"_blank\">RCKT</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3450811-rocket-pharma-down-5-after-hours-on-equity-offering\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Rocket Pharma down 5% after hours on equity offering</a></h4><ul><li>Rocket Pharmaceuticals (NASDAQ:<a href='https://seekingalpha.com/symbol/RCKT' title='Rocket Pharmaceuticals, Inc.'>RCKT</a>) slips <font color=\"red\">5%</font> after hours in reaction to its planned <a href=\"https://seekingalpha.com/pr/17476946-rocket-pharmaceuticals-announces-proposed-public-offering-common-stock\" target=\"_blank\">public offering</a> of common stock. Price, volume and terms have yet to be announced.</li></ul><div class=\"tiny-share-widget\" data-id=\"3450811\" data-linked=\"Rocket Pharma down 5% after hours on equity offering\" data-tweet=\"$RCKT - Rocket Pharma down 5% after hours on equity offering https://seekingalpha.com/news/3450811-rocket-pharma-down-5-after-hours-on-equity-offering?source=tweet\" data-url=\"https://seekingalpha.com/news/3450811-rocket-pharma-down-5-after-hours-on-equity-offering\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  4:04 PM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3450805\" data-ts=\"1555358184\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/VIA\" target=\"_blank\">VIA</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3450805-viacom-perky-on-cbs-merger-chatter\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Viacom perky on CBS merger chatter</a></h4><ul><li><a href=\"https://twitter.com/CGasparino/status/1117871787801362433\" target=\"_blank\">According to Charlie Gasparino</a>, talks between Viacom (<a href='https://seekingalpha.com/symbol/VIA' title='Viacom Inc.'>VIA</a> <font color='green'>+1.8%</font>) and CBS (<a href='https://seekingalpha.com/symbol/CBS' title='CBS Corporation'>CBS</a> <font color='green'>+0.2%</font>) are heating up, and delaying the search for a new CEO at CBS.</li><li>Viacom chief Robert Bakish, says Gasparino, is seen with the inside track for the CEO's job should the merger happen now.</li></ul><div class=\"tiny-share-widget\" data-id=\"3450805\" data-linked=\"Viacom perky on CBS merger chatter\" data-tweet=\"$VIA $CBS $VIAB - Viacom perky on CBS merger chatter https://seekingalpha.com/news/3450805-viacom-perky-on-cbs-merger-chatter?source=tweet\" data-url=\"https://seekingalpha.com/news/3450805-viacom-perky-on-cbs-merger-chatter\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  3:56 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>13&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3450799\" data-ts=\"1555356908\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/BKNG\" target=\"_blank\">BKNG</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3450799-joel-greenblatt-talks-up-booking-holdings\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Joel Greenblatt talks up Booking Holdings</a></h4><ul> <li>Booking Holdings (<a href='https://seekingalpha.com/symbol/BKNG' title='Booking Holdings Inc.'>BKNG</a> <font color='green'>+0.7%</font>) is called a compelling investment <a href=\"https://www.cnbc.com/2019/04/15/joel-greenblatt-says-he-likes-booking-thinks-align-is-too-expensive.html\" target=\"_blank\">idea</a> by value investor Joel Greenblatt.</li> <li>Greenblatt thinks the stock's cheaper price and solid growth in earnings and sales are enough to offset concerns on competition from Google and Airbnb.</li> <li>\"It\u2019s an asset-light, cash flow machine. It's in a very good business, it's essentially in a duopoly with Expedia,\" he tells CNBC.</li> <li>BKNG currently trades about 16% below its 52-week high.</li> </ul><div class=\"tiny-share-widget\" data-id=\"3450799\" data-linked=\"Joel Greenblatt talks up Booking Holdings\" data-tweet=\"$BKNG - Joel Greenblatt talks up Booking Holdings https://seekingalpha.com/news/3450799-joel-greenblatt-talks-up-booking-holdings?source=tweet\" data-url=\"https://seekingalpha.com/news/3450799-joel-greenblatt-talks-up-booking-holdings\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  3:35 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>8&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3450796\" data-ts=\"1555354796\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/WM\" target=\"_blank\">WM</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3450796-waste-management-deal-for-advanced-disposal-wins-wall-street-kudos\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Waste Management deal for Advanced Disposal wins Wall Street kudos</a></h4><ul><li>Waste Management (<a href='https://seekingalpha.com/symbol/WM' title='Waste Management, Inc.'>WM</a> <font color='green'>+2.6%</font>) pushes to a 52-week high and Advanced Disposal Services (<a href='https://seekingalpha.com/symbol/ADSW' title='Advanced Disposal Services, Inc.'>ADSW</a> <font color='green'>+18.8%</font>) soars to all-time highs following the announced <a href=\"https://seekingalpha.com/news/3450544-waste-management-5b-deal-advanced-disposal\" target=\"_blank\">merger</a> of the no. 1 and no. 4 waste management services providers.</li><li><a href=\"https://www.barrons.com/articles/waste-management-deal-advanced-disposal-services-stock-acquisition-51555336612\" target=\"_blank\">Wall Street likes the deal</a>, as WM paid less than 11x estimated 2019 EBITDA, less than its current 12x EBITDA valuation multiple.</li><li>BMO analyst Jeffrey Silber says WM's debt-leverage ratio is expected to remain within its long-term target debt-to-EBITDA range of 2.8x-3x, and the company is not stretching its balance sheet too thin to make the acquisition.</li><li>WM is <a href=\"https://thefly.com/thestreet/realmoney/index.php/WM;ADSWid2892627/WM;ADSW-Stifel-upgrades-Waste-Management-Advanced-Disposal-each-to-Buy-after-deal\" target=\"_blank\">upgraded to Buy</a> at Stifel just days after the firm <a href=\"https://seekingalpha.com/news/3449964-waste-stocks-downgraded-stifel-seeing-recycling-headwinds\" target=\"_blank\">cut shares to Neutral</a>, saying adding ADSW \"dramatically lowers\" its cost of capital, reduces capital spending and stimulates tuck-in activity that should all drive sustainable free cash flow growth.</li></ul><div class=\"tiny-share-widget\" data-id=\"3450796\" data-linked=\"Waste Management deal for Advanced Disposal wins Wall Street kudos\" data-tweet=\"$WM $ADSW - Waste Management deal for Advanced Disposal wins Wall Street kudos https://seekingalpha.com/news/3450796-waste-management-deal-for-advanced-disposal-wins-wall-street-kudos?source=tweet\" data-url=\"https://seekingalpha.com/news/3450796-waste-management-deal-for-advanced-disposal-wins-wall-street-kudos\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  2:59 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>5&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3450789\" data-ts=\"1555354413\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/\" target=\"_blank\"></a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3450789-efii-gogo-and-hmi-among-notable-tech-movers\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">EFII, GOGO and HMI among notable tech movers</a></h4><ul><li><strong>Gainers: </strong>Electronics for Imaging, Inc. (NASDAQ:<a href='https://seekingalpha.com/symbol/EFII' title='Electronics for Imaging, Inc.'>EFII</a>) <font color=\"green\">+30%</font>. Zedge, Inc. (NYSEMKT:<a href='https://seekingalpha.com/symbol/ZDGE' title='Zedge, Inc.'>ZDGE</a>) <font color=\"green\">+14%</font>. Phunware Inc. (PHUN) <font color=\"green\">+12%</font>. Gogo Inc. (NASDAQ:<a href='https://seekingalpha.com/symbol/GOGO' title='Gogo Inc.'>GOGO</a>) <font color=\"green\">+12%</font>. Boxlight Corporation (NASDAQ:<a href='https://seekingalpha.com/symbol/BOXL' title='Boxlight Corporation'>BOXL</a>) <font color=\"green\">+9%</font>.</li> <li><strong>Losers: </strong>Summit Wireless Technologies, Inc. (NASDAQ:<a href='https://seekingalpha.com/symbol/WISA' title='Summit Wireless Technologies, Inc.'>WISA</a>) <font color=\"red\">-11%</font>. Gridsum Holding Inc. (NASDAQ:<a href='https://seekingalpha.com/symbol/GSUM' title='Gridsum Holding Inc.'>GSUM</a>) <font color=\"red\">-9%</font>. Xunlei Limited (NASDAQ:<a href='https://seekingalpha.com/symbol/XNET' title='Xunlei Limited'>XNET</a>) <font color=\"red\">-9%</font>. Inpixon (NASDAQ:<a href='https://seekingalpha.com/symbol/INPX' title='Inpixon'>INPX</a>) <font color=\"red\">-9%</font>. Huami Corporation (NYSE:<a href='https://seekingalpha.com/symbol/HMI' title='Huami Corporation'>HMI</a>) <font color=\"red\">-8%</font>.</li> </ul><div class=\"tiny-share-widget\" data-id=\"3450789\" data-linked=\"EFII, GOGO and HMI among notable tech movers\" data-tweet=\"$EFII $ZDGE $GOGO - EFII, GOGO and HMI among notable tech movers https://seekingalpha.com/news/3450789-efii-gogo-and-hmi-among-notable-tech-movers?source=tweet\" data-url=\"https://seekingalpha.com/news/3450789-efii-gogo-and-hmi-among-notable-tech-movers\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  2:53 PM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3450786\" data-ts=\"1555353322\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/SHOS\" target=\"_blank\">SHOS</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3450786-esl-partners-pressures-sears-hometown-and-outlet-stores\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">ESL Partners pressures Sears Hometown and Outlet Stores</a></h4><ul> <li>Sears Hometown and Outlet Stores (NASDAQ:<a href='https://seekingalpha.com/symbol/SHOS' title='Sears Hometown and Outlet Stores, Inc.'>SHOS</a>) is <font color=\"red\">down 3.0%</font> amid some drama with ESL Partners.</li> <li>ESL Partners disclosed that it ousted two SHOS board members and changed bylaws to prevent the company from moving forward with a liquidation of its Hometown business.</li> <li>\"We encourage the board to consider alternatives to a liquidation of the Hometown Business,\" says ESL in its filing.</li> <li><a href=\"https://seekingalpha.com/filing/4444394\" target=\"_blank\">SEC Form 13D</a></li> </ul><div class=\"tiny-share-widget\" data-id=\"3450786\" data-linked=\"ESL Partners pressures Sears Hometown and Outlet Stores\" data-tweet=\"$SHOS - ESL Partners pressures Sears Hometown and Outlet Stores https://seekingalpha.com/news/3450786-esl-partners-pressures-sears-hometown-and-outlet-stores?source=tweet\" data-url=\"https://seekingalpha.com/news/3450786-esl-partners-pressures-sears-hometown-and-outlet-stores\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  2:35 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>79&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3450779\" data-ts=\"1555351900\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/LYFT\" target=\"_blank\">LYFT</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3450779-lyft-continues-post-ipo-declines\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Lyft continues post-IPO declines</a></h4><ul><li>Active short selling in Lyft (NASDAQ:<a href='https://seekingalpha.com/symbol/LYFT' title='Lyft, Inc.'>LYFT</a>) has pushed its free float held short to 75%, according to <a href=\"https://www.bloomberg.com/news/articles/2019-04-15/lyft-shares-continue-to-slide-as-short-bets-keep-piling-up\" target=\"_blank\">S3 Partners data</a>.</li><li>On Friday, S3 said short sellers were up $43M in mark-to-market profits, bringing their total post-IPO profits to $202.4M.</li><li>Lyft shares dropped on last week's <a href=\"https://seekingalpha.com/news/3450150-uber-files-1b-ipo\" target=\"_blank\">Uber IPO filing</a>. Shares are <font color=\"red\">down 5.7%</font> today after <a href=\"https://seekingalpha.com/news/3450509-lyft-pulls-electric-bikes-three-u-s-cities\" target=\"_blank\">pulling electric bikes</a> in three cities for braking problems.</li></ul><div class=\"tiny-share-widget\" data-id=\"3450779\" data-linked=\"Lyft continues post-IPO declines\" data-tweet=\"$LYFT - Lyft continues post-IPO declines https://seekingalpha.com/news/3450779-lyft-continues-post-ipo-declines?source=tweet\" data-url=\"https://seekingalpha.com/news/3450779-lyft-continues-post-ipo-declines\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  2:11 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>34&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3450771\" data-ts=\"1555351107\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/\" target=\"_blank\"></a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3450771-amyris-and-senestech-among-energy-materials-gainers-roan-resources-and-platinum-group-metals\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Amyris and SenesTech among Energy/Materials gainers; Roan Resources and Platinum Group Metals among losers</a></h4><ul><li><b>Gainers: </b>Amyris (NASDAQ:<a href='https://seekingalpha.com/symbol/AMRS' title='Amyris, Inc.'>AMRS</a>) <font color=\"green\">+13%</font>. SenesTech (NASDAQ:<a href='https://seekingalpha.com/symbol/SNES' title='SenesTech, Inc.'>SNES</a>) <font color=\"green\">+10%</font>. Covia (NYSE:<a href='https://seekingalpha.com/symbol/CVIA' title='Covia Holdings Corporation'>CVIA</a>) <font color=\"green\">+8%</font>. Ossen Innovation (NASDAQ:<a href='https://seekingalpha.com/symbol/OSN' title='Ossen Innovation Co., Ltd.'>OSN</a>) <font color=\"green\">+7%</font>. Valhi (NYSE:<a href='https://seekingalpha.com/symbol/VHI' title='Valhi, Inc.'>VHI</a>) <font color=\"green\">+6%</font>.</li><li><b>Losers: </b>Roan Resources (NYSE:<a href='https://seekingalpha.com/symbol/ROAN' title='Roan Resources, Inc.'>ROAN</a>) <font color=\"red\">-9%</font>. Platinum Group Metals (NYSEMKT:<a href='https://seekingalpha.com/symbol/PLG' title='Platinum Group Metals Ltd.'>PLG</a>) <font color=\"red\">-8%</font>. ZK International Group (NASDAQ:<a href='https://seekingalpha.com/symbol/ZKIN' title='ZK International Group Co., Ltd.'>ZKIN</a>) <font color=\"red\">-8%</font>. Bristow Group (NYSE:<a href='https://seekingalpha.com/symbol/BRS' title='Bristow Group Inc.'>BRS</a>) <font color=\"red\">-8%</font>. Pacific Ethanol (NASDAQ:<a href='https://seekingalpha.com/symbol/PEIX' title='Pacific Ethanol, Inc.'>PEIX</a>) <font color=\"red\">-8%</font>.</li></ul><div class=\"tiny-share-widget\" data-id=\"3450771\" data-linked=\"Amyris and SenesTech among Energy/Materials gainers; Roan Resources and Platinum Group Metals among losers\" data-tweet=\"$AMRS $SNES $CVIA - Amyris and SenesTech among Energy/Materials gainers; Roan Resources and Platinum Group Metals among losers https://seekingalpha.com/news/3450771-amyris-and-senestech-among-energy-materials-gainers-roan-resources-and-platinum-group-metals?source=tweet\" data-url=\"https://seekingalpha.com/news/3450771-amyris-and-senestech-among-energy-materials-gainers-roan-resources-and-platinum-group-metals\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  1:58 PM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3450753\" data-ts=\"1555349112\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/GS\" target=\"_blank\">GS</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3450753-banks-follow-goldmans-citis-decline\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Banks follow Goldman&#39;s, Citi&#39;s decline</a></h4><ul><li>While Goldman Sachs (<a href='https://seekingalpha.com/symbol/GS' title='The Goldman Sachs Group, Inc.'>GS</a> <font color='red'>-3.2%</font>) and Citigroup (<a href='https://seekingalpha.com/symbol/C' title='Citigroup Inc.'>C</a> <font color='red'>-0.1%</font>) Q1 earnings exceeded consensus estimates, investors weren't impressed and bank stocks, in general, slumped.</li><li>Financial Select Sector SPDR ETF (NYSEARCA:<a href='https://seekingalpha.com/symbol/XLF' title='Financial Select Sector SPDR ETF'>XLF</a>) <font color=\"red\">slides 0.8%</font> in early afternoon trading, backtracking from Friday's 1.8% gain, its largest since April 1.</li><li>Goldman Chairman and CEO David Solomon stressed that the bank is \"focused on new opportunities to grow and diversify our business mix\" and called the results a \"muted\" start to the year. Goldman's stock is the biggest decliner in the Dow Jones Industrial Average, which is down 0.2%.</li><li>The only U.S. megabank that's up, Wells Fargo (<a href='https://seekingalpha.com/symbol/WFC' title='Wells Fargo & Company'>WFC</a> <font color='green'>+0.7%</font>), is the only one that fell on Friday.</li><li>The other big banks: Bank of America (<a href='https://seekingalpha.com/symbol/BAC' title='Bank of America Corporation'>BAC</a> <font color='red'>-1.1%</font>), JPMorgan (<a href='https://seekingalpha.com/symbol/JPM' title='JPMorgan Chase & Co.'>JPM</a> <font color='red'>-1.4%</font>), Morgan Stanley (<a href='https://seekingalpha.com/symbol/MS' title='Morgan Stanley'>MS</a> <font color='red'>-1.2%</font>).</li><li>Regional banks followed suit, as M&amp;T Bank (<a href='https://seekingalpha.com/symbol/MTB' title='M&T Bank Corporation'>MTB</a> <font color='red'>-2.2%</font>) fell despite Q1 EPS beating its average analyst estimate. Others: PNC Financial (<a href='https://seekingalpha.com/symbol/PNC' title='The PNC Financial Services Group, Inc.'>PNC</a> <font color='red'>-0.3%</font>), Axos Financial (<a href='https://seekingalpha.com/symbol/AX' title='Axos Financial, Inc.'>AX</a> <font color='red'>-0.9%</font>), Bank OZK  (<a href='https://seekingalpha.com/symbol/OZK' title='Bank OZK'>OZK</a> <font color='red'>-2.6%</font>), Fifth Third (<a href='https://seekingalpha.com/symbol/FITB' title='Fifth Third Bancorp'>FITB</a> <font color='red'>-1.6%</font>), KeyCorp (<a href='https://seekingalpha.com/symbol/KEY' title='KeyCorp'>KEY</a> <font color='red'>-1.3%</font>), CIT Group (<a href='https://seekingalpha.com/symbol/CIT' title='CIT Group Inc.'>CIT</a> <font color='red'>-1.2%</font>).</li><li>Many non-U.S-based multinational banks are faring better--Lloyds Banking Group (<a href='https://seekingalpha.com/symbol/LYG' title='Lloyds Banking Group plc'>LYG</a> <font color='green'>+0.9%</font>), Barclays (<a href='https://seekingalpha.com/symbol/BCS' title='Barclays PLC'>BCS</a> <font color='green'>+0.6%</font>), Royal Bank of Scotland (<a href='https://seekingalpha.com/symbol/RBS' title='The Royal Bank of Scotland Group plc'>RBS</a> <font color='green'>+0.5%</font>), and Credit Suisse Group (<a href='https://seekingalpha.com/symbol/CS' title='Credit Suisse Group AG'>CS</a> <font color='green'>+0.6%</font>).</li><li>Previously: <a href=\"https://seekingalpha.com/news/3450581-goldman-seeks-diversify-business-mix-muted-q1\" target=\"_blank\">Goldman seeks to diversify business mix after muted Q1</a> (April 15)</li><li>ETFs: <a href='https://seekingalpha.com/symbol/KRE' title='SPDR S&P Regional Banking ETF'>KRE</a>, <a href='https://seekingalpha.com/symbol/KBE' title='SPDR S&P Bank ETF'>KBE</a>, <a href='https://seekingalpha.com/symbol/EUFN' title='iShares MSCI Europe Financials Sector Index ETF'>EUFN</a>, <a href='https://seekingalpha.com/symbol/PSP' title='Invesco Global Listed Private Equity Portfolio ETF'>PSP</a>, <a href='https://seekingalpha.com/symbol/IAT' title='iShares U.S. Regional Banks ETF'>IAT</a>, <a href='https://seekingalpha.com/symbol/KBWB' title='Invesco KBW Bank Portfolio ETF'>KBWB</a>, <a href='https://seekingalpha.com/symbol/QABA' title='First Trust Nasdaq ABA Community Bank ETF'>QABA</a>, <a href='https://seekingalpha.com/symbol/KBWR' title='Invesco KBW Regional Banking Portfolio ETF'>KBWR</a>, <a href='https://seekingalpha.com/symbol/PEX' title='ProShares Global Listed Private Equity ETF'>PEX</a>, <a href='https://seekingalpha.com/symbol/DPST' title='Direxion Daily Regional Banks Bull 3x Shares ETF'>DPST</a>, <a href='https://seekingalpha.com/symbol/IXG' title='iShares Global Financials ETF'>IXG</a>, <a href='https://seekingalpha.com/symbol/EUFL' title='Direxion Daily European Financials Bull 2X Shares ETF'>EUFL</a>, <a href='https://seekingalpha.com/symbol/WDRW' title='Direxion Daily Regional Banks Bear 3x Shares ETF'>WDRW</a>, <a href='https://seekingalpha.com/symbol/FTXO' title='First Trust Nasdaq Bank ETF'>FTXO</a>, <a href='https://seekingalpha.com/symbol/DFNL' title='Davis Select Financial ETF'>DFNL</a>, <a href='https://seekingalpha.com/symbol/BNKD' title='Rex Shares MicroSectors U.S. Big Banks Index -3X Inverse Leveraged ETN'>BNKD</a>, <a href='https://seekingalpha.com/symbol/BNKO' title='Rex Shares MicroSectors U.S. Big Banks Index 2X Leveraged ETN'>BNKO</a>, <a href='https://seekingalpha.com/symbol/BNKU' title='Rex Shares MicroSectors U.S. Big Banks Index 3X Leveraged ETN'>BNKU</a>, <a href='https://seekingalpha.com/symbol/BNKZ' title='Rex Shares MicroSectors U.S. Big Banks Index -2X Inverse Leveraged ETN'>BNKZ</a>, <a href='https://seekingalpha.com/symbol/KNAB' title='Rex Shares MicroSectors U.S. Big Banks Index Inverse ETN'>KNAB</a></li></ul><div class=\"tiny-share-widget\" data-id=\"3450753\" data-linked=\"Banks follow Goldman&#39;s, Citi&#39;s decline\" data-tweet=\"$GS $C $XLF - Banks follow Goldman&#39;s, Citi&#39;s decline https://seekingalpha.com/news/3450753-banks-follow-goldmans-citis-decline?source=tweet\" data-url=\"https://seekingalpha.com/news/3450753-banks-follow-goldmans-citis-decline\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  1:25 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>20&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3450751\" data-ts=\"1555348676\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/NFLX\" target=\"_blank\">NFLX</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3450751-netflix-dips-again-ahead-of-earnings\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Netflix dips again ahead of earnings</a></h4><ul><li>Shares of Netflix (NASDAQ:<a href='https://seekingalpha.com/symbol/NFLX' title='Netflix, Inc.'>NFLX</a>) are <font color=\"red\">down another 1.90%</font> as selling pressure following the Disney+ unveiling extends for another session.</li><li>MarketWatch's Jeffrey Reeves says it's way too early to ring any sort of death knell for the streamer due to the new competition.</li><li>Reeves notes that what Disney offers in star power, Netflix offers in first-mover advantage and a native digital platform that is \"in-step\" with how streaming-video audiences consume content. \"Maybe it won\u2019t crank out blockbusters with big merchandising deals, but you can be sure that Netflix will keep you binging on stuff that connected with you personally. That adds up to staying power, and should support the recent price increase in its service,\" he writes.</li><li>Netflix reports earnings after the closing bell tomorrow. A few NFLX consensus marks to watch: revenue $4.50B, operating income $408M, EPS $0.57, domestic streaming net adds +1.38M, international streaming net adds +6.52M.</li><li>Shares of Netflix are up 29% YTD even after a couple of shaky days of trading.</li></ul><div class=\"tiny-share-widget\" data-id=\"3450751\" data-linked=\"Netflix dips again ahead of earnings\" data-tweet=\"$NFLX - Netflix dips again ahead of earnings https://seekingalpha.com/news/3450751-netflix-dips-again-ahead-of-earnings?source=tweet\" data-url=\"https://seekingalpha.com/news/3450751-netflix-dips-again-ahead-of-earnings\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  1:17 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>88&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3450749\" data-ts=\"1555348088\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/\" target=\"_blank\"></a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3450749-national-holdings-leads-financial-gainers-xinyuan-real-estate-and-dunxin-financial-holdings\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">National Holdings leads financial gainers; Xinyuan Real Estate and Dunxin Financial Holdings among losers</a></h4><ul><li><b>Gainers:</b> National Holdings (NASDAQ:<a href='https://seekingalpha.com/symbol/NHLD' title='National Holdings Corporation'>NHLD</a>) <font color=\"green\">+11%</font>. Mogo Finance Technology (NASDAQ:<a href='https://seekingalpha.com/symbol/MOGO' title='Mogo Finance Technology Inc.'>MOGO</a>) <font color=\"green\">+10%</font>. Oxbridge Re Holdings (NASDAQ:<a href='https://seekingalpha.com/symbol/OXBR' title='Oxbridge Re Holdings Limited'>OXBR</a>) <font color=\"green\">+7%</font>.</li><li><b>Losers:</b> Hexindai (NASDAQ:<a href='https://seekingalpha.com/symbol/HX' title='Hexindai Inc.'>HX</a>) <font color=\"red\">-8%</font>. Dunxin Financial Holdings (NYSEMKT:<a href='https://seekingalpha.com/symbol/DXF' title='Dunxin Financial Holdings Limited'>DXF</a>) <font color=\"red\">-7%</font>. Xinyuan Real Estate (NYSE:<a href='https://seekingalpha.com/symbol/XIN' title='Xinyuan Real Estate Co., Ltd.'>XIN</a>) <font color=\"red\">-7%</font>. CBL &amp; Associates Properties (NYSE:<a href='https://seekingalpha.com/symbol/CBL' title='CBL & Associates Properties, Inc'>CBL</a>) <font color=\"red\">-7%</font>. Atlas Financial Holdings (NASDAQ:<a href='https://seekingalpha.com/symbol/AFH' title='Atlas Financial Holdings, Inc.'>AFH</a>) <font color=\"red\">-6%</font>.</li></ul><div class=\"tiny-share-widget\" data-id=\"3450749\" data-linked=\"National Holdings leads financial gainers; Xinyuan Real Estate and Dunxin Financial Holdings among losers\" data-tweet=\"$NHLD $MOGO $OXBR - National Holdings leads financial gainers; Xinyuan Real Estate and Dunxin Financial Holdings among losers https://seekingalpha.com/news/3450749-national-holdings-leads-financial-gainers-xinyuan-real-estate-and-dunxin-financial-holdings?source=tweet\" data-url=\"https://seekingalpha.com/news/3450749-national-holdings-leads-financial-gainers-xinyuan-real-estate-and-dunxin-financial-holdings\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  1:08 PM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3450747\" data-ts=\"1555347763\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/\" target=\"_blank\"></a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3450747-briggs-stratton-and-dmc-global-among-industrial-gainers-mict-and-forterra-among-losers\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Briggs &amp; Stratton and DMC Global among industrial gainers; MICT and Forterra among losers</a></h4><ul><li><b>Gainers: </b>Advanced Disposal Services (NYSE:<a href='https://seekingalpha.com/symbol/ADSW' title='Advanced Disposal Services, Inc.'>ADSW</a>) <font color=\"green\">+19%</font>. Loma Negra Compania Industrial (NYSE:<a href='https://seekingalpha.com/symbol/LOMA' title='Loma Negra Compañía Industrial Argentina Sociedad Anónima'>LOMA</a>) <font color=\"green\">+7%</font>. DMC Global (NASDAQ:<a href='https://seekingalpha.com/symbol/BOOM' title='DMC Global Inc.'>BOOM</a>) <font color=\"green\">+6%</font>. Briggs &amp; Stratton (NYSE:<a href='https://seekingalpha.com/symbol/BGG' title='Briggs & Stratton Corporation'>BGG</a>) <font color=\"green\">+6%</font>.</li><li><b>Losers: </b>MICT (NASDAQ:<a href='https://seekingalpha.com/symbol/MICT' title='MICT, Inc.'>MICT</a>) <font color=\"red\">-13%</font>. Euro Tech Holdings (NASDAQ:<a href='https://seekingalpha.com/symbol/CLWT' title='Euro Tech Holdings Company Limited'>CLWT</a>) <font color=\"red\">-10%</font>. Forterra (NASDAQ:<a href='https://seekingalpha.com/symbol/FRTA' title='Forterra, Inc.'>FRTA</a>) <font color=\"red\">-5%</font>.</li></ul><div class=\"tiny-share-widget\" data-id=\"3450747\" data-linked=\"Briggs &amp; Stratton and DMC Global among industrial gainers; MICT and Forterra among losers\" data-tweet=\"$ADSW $LOMA $BOOM - Briggs &amp; Stratton and DMC Global among industrial gainers; MICT and Forterra among losers https://seekingalpha.com/news/3450747-briggs-stratton-and-dmc-global-among-industrial-gainers-mict-and-forterra-among-losers?source=tweet\" data-url=\"https://seekingalpha.com/news/3450747-briggs-stratton-and-dmc-global-among-industrial-gainers-mict-and-forterra-among-losers\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  1:02 PM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3450745\" data-ts=\"1555347548\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/ROAN\" target=\"_blank\">ROAN</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3450745-roan-resources-sinks-to-all-time-lows-after-surprise-ceo-departure\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Roan Resources sinks to all-time lows after surprise CEO departure</a></h4><ul><li>Roan Resources (<a href='https://seekingalpha.com/symbol/ROAN' title='Roan Resources, Inc.'>ROAN</a> <font color='red'>-11.7%</font>) plunges as low as $4.95/share after Chairman and CEO Tony Maranto <a href=\"https://seekingalpha.com/news/3450584-roan-resources-ceo-maranto-resigns\" target=\"_blank\">resigns for personal reasons</a>, replaced on an interim basis by board member Joseph Mills.</li><li>Mills also commented on Q4 well action, saying Q4 wells \"continue to demonstrate an attractively low decline rate\" under the company's pressure management techniques.</li><li>Mills says 15 of Roan's Q4 wells have achieved at least 120 days of production, with an average 120-day production rate of 1,036 boe/day (48% oil, 22% natural gas liquids, 30% gas), vs. the average 90-day rate of 1,089 boe/day for the identical well set.</li></ul><div class=\"tiny-share-widget\" data-id=\"3450745\" data-linked=\"Roan Resources sinks to all-time lows after surprise CEO departure\" data-tweet=\"$ROAN - Roan Resources sinks to all-time lows after surprise CEO departure https://seekingalpha.com/news/3450745-roan-resources-sinks-to-all-time-lows-after-surprise-ceo-departure?source=tweet\" data-url=\"https://seekingalpha.com/news/3450745-roan-resources-sinks-to-all-time-lows-after-surprise-ceo-departure\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 12:59 PM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3450740\" data-ts=\"1555347042\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/PULM\" target=\"_blank\">PULM</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3450740-pulmazole-collaboration-deal-fails-to-lift-pulmatrix-down-7\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Pulmazole collaboration deal fails to lift Pulmatrix, down 7%</a></h4><ul><li>Pulmatrix (<a href='https://seekingalpha.com/symbol/PULM' title='Pulmatrix, Inc.'>PULM</a> <font color=\"red\">-7.1%</font>) is down on more than 60% higher volume on the heels of an <a href=\"https://seekingalpha.com/pr/17476384-pulmatrix-cipla-technologies-llc-enter-definitive-agreement-development-commercialization\" target=\"_blank\">agreement </a>with Cipla Limited subsidiary Cipla Technologies to develop and commercialize Pulmazole (itraconazole) for the treatment of allergic bronchopulmonary aspergillosis &#40;ABPA&#41; in asthma patients, a deal that appears to disappoint investors.</li><li>Under the terms of the partnership, PULM will receive $22M upfront in exchange for an exclusive license to Cipla Tech for pulmonary indications. The parties will equally share future development and commercialization costs as well as global free cash flow from product sales.</li><li>PULM will be primarily responsible for clinical development and Cipla Tech will be responsible for commercialization.</li><li>With the influx of new capital, PULM plans to launch a Phase 2 study in ABPA in asthma patients this month.</li></ul><div class=\"tiny-share-widget\" data-id=\"3450740\" data-linked=\"Pulmazole collaboration deal fails to lift Pulmatrix, down 7%\" data-tweet=\"$PULM - Pulmazole collaboration deal fails to lift Pulmatrix, down 7% https://seekingalpha.com/news/3450740-pulmazole-collaboration-deal-fails-to-lift-pulmatrix-down-7?source=tweet\" data-url=\"https://seekingalpha.com/news/3450740-pulmazole-collaboration-deal-fails-to-lift-pulmatrix-down-7\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 12:50 PM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3450735\" data-ts=\"1555346172\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/\" target=\"_blank\"></a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3450735-midday-movers-and-shakers\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Midday movers and shakers</a></h4><ul><li><strong>Gainers</strong>: Fibrocell Science (NASDAQ:<a href='https://seekingalpha.com/symbol/FCSC' title='Fibrocell Science, Inc.'>FCSC</a>) <font color=\"green\">+52%</font>. Bio-Path Holdings (NASDAQ:<a href='https://seekingalpha.com/symbol/BPTH' title='Bio-Path Holdings, Inc.'>BPTH</a>) <font color=\"green\">+40%</font>. Vectrus (NYSE:<a href='https://seekingalpha.com/symbol/VEC' title='Vectrus, Inc.'>VEC</a>) <font color=\"green\">+27%</font>. Electronics for Imaging (NASDAQ:<a href='https://seekingalpha.com/symbol/EFII' title='Electronics for Imaging, Inc.'>EFII</a>) <font color=\"green\">+27%</font>.  SSLJ.com (NASDAQ:<a href='https://seekingalpha.com/symbol/SSLJ' title='SSLJ.com Limited'>SSLJ</a>) <font color=\"green\">+22%</font>. ATA (NASDAQ:<a href='https://seekingalpha.com/symbol/ATAI' title='ATA Inc.'>ATAI</a>) <font color=\"green\">+21%</font>. Advanced Disposal Services (NYSE:<a href='https://seekingalpha.com/symbol/ADSW' title='Advanced Disposal Services, Inc.'>ADSW</a>) <font color=\"green\">+19%</font>. Amyris (NASDAQ:<a href='https://seekingalpha.com/symbol/AMRS' title='Amyris, Inc.'>AMRS</a>) <font color=\"green\">+17%</font>. Zedge (NYSEMKT:<a href='https://seekingalpha.com/symbol/ZDGE' title='Zedge, Inc.'>ZDGE</a>) <font color=\"green\">+14%</font>. Gogo (NASDAQ:<a href='https://seekingalpha.com/symbol/GOGO' title='Gogo Inc.'>GOGO</a>) <font color=\"green\">+13%</font>.</li> <li><strong>Losers</strong>: Reebonz Holding (NASDAQ:<a href='https://seekingalpha.com/symbol/RBZ' title='Reebonz Holding Limited'>RBZ</a>) <font color=\"red\">-54%</font>. Conatus Pharmaceuticals (NASDAQ:<a href='https://seekingalpha.com/symbol/CNAT' title='Conatus Pharmaceuticals Inc.'>CNAT</a>) <font color=\"red\">-31%</font>. Assembly Biosciences (NASDAQ:<a href='https://seekingalpha.com/symbol/ASMB' title='Assembly Biosciences, Inc.'>ASMB</a>) <font color=\"red\">-23%</font>. Vaccinex (NASDAQ:<a href='https://seekingalpha.com/symbol/VCNX' title='Vaccinex, Inc.'>VCNX</a>) <font color=\"red\">-17%</font>. Aphria (NYSE:<a href='https://seekingalpha.com/symbol/APHA' title='Aphria Inc.'>APHA</a>) <font color=\"red\">-14%</font>. Sunesis Pharmaceuticals (NASDAQ:<a href='https://seekingalpha.com/symbol/SNSS' title='Sunesis Pharmaceuticals, Inc.'>SNSS</a>) <font color=\"red\">-13%</font>. MICT (NASDAQ:<a href='https://seekingalpha.com/symbol/MICT' title='MICT, Inc.'>MICT</a>) <font color=\"red\">-13%</font>. Kitov Pharma (NASDAQ:<a href='https://seekingalpha.com/symbol/KTOV' title='Kitov Pharma Ltd'>KTOV</a>) <font color=\"red\">-13%</font>. Clovis Oncology (NASDAQ:<a href='https://seekingalpha.com/symbol/CLVS' title='Clovis Oncology, Inc.'>CLVS</a>) <font color=\"red\">-13%</font>. Fred's (NASDAQ:<a href='https://seekingalpha.com/symbol/FRED' title='Fred&#39;s, Inc.'>FRED</a>) <font color=\"red\">-13%</font>.</li> </ul><div class=\"tiny-share-widget\" data-id=\"3450735\" data-linked=\"Midday movers and shakers\" data-tweet=\"$FCSC $BPTH $VEC - Midday movers and shakers https://seekingalpha.com/news/3450735-midday-movers-and-shakers?source=tweet\" data-url=\"https://seekingalpha.com/news/3450735-midday-movers-and-shakers\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 12:36 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>4&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3450734\" data-ts=\"1555346097\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/\" target=\"_blank\"></a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3450734-bmw-deutsche-telekom-urge-germany-to-oppose-wi-fi-connected-cars\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">BMW, Deutsche Telekom urge Germany to oppose Wi-Fi connected cars</a></h4><ul>   <li>Chief executives at Deutsche Telekom (<a href=\"http://seekingalpha.com/symbol/DTEGY\" target=\"_blank\">DTEGY</a> <font color=\"green\">+0.5%</font>) and BMW (<a href=\"http://seekingalpha.com/symbol/BMWYY\" target=\"_blank\">BMWYY</a> <font color=\"green\">+0.6%</font>) are pushing Germany to <a href=\"https://www.reuters.com/article/us-eu-autos-technology/german-bosses-urge-government-to-stop-eu-proposal-on-connected-cars-idUSKCN1RR1OW\" target=\"_blank\">oppose an EU proposal</a> that might set a standard for connected cars based on Wi-Fi, rather than 5G.</li>    <li>\u201cWe are convinced that mandating Wi-Fi technology will cause significant delay to the European rollout of car-to-car and car-to-infrastructure communication,\u201d write BMW's Harald Krueger and Deutsche Telekom's Tim Hoettges.</li>    <li>Germany says it's reviewing reservations raised by legal advisers before it takes a final position on the issue.</li>    <li>But carmakers are lined up across from each other amid a pair of competing standards: the Wi-Fi-based ITS-G5 standard, which would give Volkswagen (<a href=\"http://seekingalpha.com/symbol/VWAGY\" target=\"_blank\">VWAGY</a> <font color=\"green\">+0.9%</font>) and Renault (<a href=\"http://seekingalpha.com/symbol/RNLSY\" target=\"_blank\">RNLSY</a> <font color=\"red\">-0.3%</font>) the edge, and the 5G-based C-V2X, which would favor BMW, Daimler (<a href=\"http://seekingalpha.com/symbol/DMLRY\" target=\"_blank\">DMLRY</a> <font color=\"red\">-0.6%</font>), Ford (<a href=\"http://seekingalpha.com/symbol/F\" target=\"_blank\">F</a> <font color=\"red\">-1.9%</font>) and PSA Group.</li> </ul><div class=\"tiny-share-widget\" data-id=\"3450734\" data-linked=\"BMW, Deutsche Telekom urge Germany to oppose Wi-Fi connected cars\" data-tweet=\"$DTEGY $BMWYY $VWAGY - BMW, Deutsche Telekom urge Germany to oppose Wi-Fi connected cars https://seekingalpha.com/news/3450734-bmw-deutsche-telekom-urge-germany-to-oppose-wi-fi-connected-cars?source=tweet\" data-url=\"https://seekingalpha.com/news/3450734-bmw-deutsche-telekom-urge-germany-to-oppose-wi-fi-connected-cars\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 12:34 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>25&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3450725\" data-ts=\"1555344115\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/\" target=\"_blank\"></a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3450725-dean-foods-and-adient-among-consumer-gainers-energous-and-future-fintech-group-among-losers\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Dean Foods and Adient among consumer gainers; Energous and Future FinTech Group among losers</a></h4><ul><li><b>Gainers: </b>Adient (NYSE:<a href='https://seekingalpha.com/symbol/ADNT' title='Adient plc'>ADNT</a>) <font color=\"green\">+12%</font>. Dean Foods (NYSE:<a href='https://seekingalpha.com/symbol/DF' title='Dean Foods Company'>DF</a>) <font color=\"green\">+9%</font>. China XD Plastics (NASDAQ:<a href='https://seekingalpha.com/symbol/CXDC' title='China XD Plastics Company Limited'>CXDC</a>) <font color=\"green\">+7%</font>. Iconix Brand Group (NASDAQ:<a href='https://seekingalpha.com/symbol/ICON' title='Iconix Brand Group, Inc.'>ICON</a>) <font color=\"green\">+5%</font>.</li><li><b>Losers: </b>Future FinTech Group (NASDAQ:<a href='https://seekingalpha.com/symbol/FTFT' title='Future FinTech Group Inc.'>FTFT</a>) <font color=\"red\">-11%</font>. Energous (NASDAQ:<a href='https://seekingalpha.com/symbol/WATT' title='Energous Corporation'>WATT</a>) <font color=\"red\">-10%</font>. The Alkaline Water Company (NASDAQ:<a href='https://seekingalpha.com/symbol/WTER' title='The Alkaline Water Company Inc.'>WTER</a>) <font color=\"red\">-7%</font>. Fuwei Films (NASDAQ:<a href='https://seekingalpha.com/symbol/FFHL' title='Fuwei Films &#40;Holdings&#41; Co., Ltd.'>FFHL</a>) <font color=\"red\">-5%</font>.</li></ul><div class=\"tiny-share-widget\" data-id=\"3450725\" data-linked=\"Dean Foods and Adient among consumer gainers; Energous and Future FinTech Group among losers\" data-tweet=\"$ADNT $DF $CXDC - Dean Foods and Adient among consumer gainers; Energous and Future FinTech Group among losers https://seekingalpha.com/news/3450725-dean-foods-and-adient-among-consumer-gainers-energous-and-future-fintech-group-among-losers?source=tweet\" data-url=\"https://seekingalpha.com/news/3450725-dean-foods-and-adient-among-consumer-gainers-energous-and-future-fintech-group-among-losers\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 12:01 PM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3450722\" data-ts=\"1555343332\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/HBM\" target=\"_blank\">HBM</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3450722-adult-supervision-urgently-needed-hudbay-activist-investor-says\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">&#39;Adult supervision urgently needed&#39; at Hudbay, activist investor says</a></h4><ul><li>Waterton Global Resources, which owns 12.1% of Hudbay Minerals (<a href='https://seekingalpha.com/symbol/HBM' title='Hudbay Minerals Inc.'>HBM</a> <font color='red'>-4.4%</font>), sends a <a href=\"https://newhudbay.com/content/uploads/2019/04/Waterton_Circular-and-Letter-to-Shareholders_4-15-19.pdf\" target=\"_blank\">letter to shareholders</a> highlighting what it considers the entrenchment and track record of poor strategic decision-making of HBM's board.</li><li>The P-E firm says HBM's \"attempts to mislead shareholders and then cover up falsehoods reveals [a] crisis of judgment at the board level,\" which proves \"adult supervision is urgently needed\" at the company.</li><li>HBM committed \"a galling lie\" in stating that \"a Bloomberg article seeded by Waterton\" artificially  manipulated the company's share price in order for Waterton to purchase  shares at a discount and increase its ownership position.</li><li>Waterton wants HBM shareholders to elect five board candidates it has nominated.</li></ul><div class=\"tiny-share-widget\" data-id=\"3450722\" data-linked=\"&#39;Adult supervision urgently needed&#39; at Hudbay, activist investor says\" data-tweet=\"$HBM - &#39;Adult supervision urgently needed&#39; at Hudbay, activist investor says https://seekingalpha.com/news/3450722-adult-supervision-urgently-needed-hudbay-activist-investor-says?source=tweet\" data-url=\"https://seekingalpha.com/news/3450722-adult-supervision-urgently-needed-hudbay-activist-investor-says\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 11:48 AM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3450709\" data-ts=\"1555342022\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/TLRY\" target=\"_blank\">TLRY</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3450709-aphria-q3-miss-weighs-on-pot-stocks\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Aphria Q3 miss weighs on pot stocks</a></h4><ul><li>The broad market's modest down move notwithstanding, cannabis stocks are under water after Aphria reported <a href=\"https://seekingalpha.com/news/3450519-aphria-misses-0_16-misses-revenue\" target=\"_blank\">fiscal Q3 results</a> (three-month period ended February 28) that came in shy of consensus. Revenue, for example, was C$73.6M, up 617% yoy, but below expectations of C$83.5M.</li><li>Selected tickers: Tilray (<a href='https://seekingalpha.com/symbol/TLRY' title='Tilray, Inc.'>TLRY</a> <font color=\"red\">-5.9%</font>), Aurora Cannabis (<a href='https://seekingalpha.com/symbol/ACB' title='Aurora Cannabis Inc.'>ACB</a> <font color=\"red\">-3.7%</font>), Cronos Group (<a href='https://seekingalpha.com/symbol/CRON' title='Cronos Group Inc.'>CRON</a> <font color=\"red\">-6.4%</font>), Canopy Growth (<a href='https://seekingalpha.com/symbol/CGC' title='Canopy Growth Corporation'>CGC</a> <font color=\"red\">-3.8%</font>)</li></ul><div class=\"tiny-share-widget\" data-id=\"3450709\" data-linked=\"Aphria Q3 miss weighs on pot stocks\" data-tweet=\"$TLRY $ACB $CRON - Aphria Q3 miss weighs on pot stocks https://seekingalpha.com/news/3450709-aphria-q3-miss-weighs-on-pot-stocks?source=tweet\" data-url=\"https://seekingalpha.com/news/3450709-aphria-q3-miss-weighs-on-pot-stocks\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 11:27 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>62&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3450704\" data-ts=\"1555341049\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/ZAYO\" target=\"_blank\">ZAYO</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3450704-zayo-group-spikes-on-report-p-e-takeover-just-days-away\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Zayo Group spikes on report P-E takeover just days away</a></h4><ul>   <li>Zayo Group (NYSE:<a href='https://seekingalpha.com/symbol/ZAYO' title='Zayo Group Holdings, Inc.'>ZAYO</a>) minutes ago spiked, pulled back and is <font color=\"green\">up 2.8%</font> after StreetInsider notes a takeover of the company is just \"days\" away with a <a href=\"https://www.streetinsider.com/Hot+M+and+A/Zayo+Group+%28ZAYO%29+Takeover+Just+Days+Away%2C+Price+Could+Reach+%2438.50Share+-+Source/15370988.html\" target=\"_blank\">price that could hit $38.50/share</a>.</li>    <li>Shares jumped as high as a <font color=\"green\">4.7% gain</font>; they're now at $31.69.</li>    <li>A private-equity consortium including Digital Colony Partners, EQT and Stonepeak Infrastructure Partners is closing in on the deal.</li> </ul><div class=\"tiny-share-widget\" data-id=\"3450704\" data-linked=\"Zayo Group spikes on report P-E takeover just days away\" data-tweet=\"$ZAYO - Zayo Group spikes on report P-E takeover just days away https://seekingalpha.com/news/3450704-zayo-group-spikes-on-report-p-e-takeover-just-days-away?source=tweet\" data-url=\"https://seekingalpha.com/news/3450704-zayo-group-spikes-on-report-p-e-takeover-just-days-away\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 11:10 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>7&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3450702\" data-ts=\"1555340906\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/\" target=\"_blank\"></a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3450702-nomura-expects-macau-sector-to-return-to-positive-growth\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Nomura expects Macau sector to return to positive growth</a></h4><ul> <li>Nomura Instinet expects a 3.8% drop in gross gaming revenue in Macau for April against a very tough comparison from a year ago of +28%.</li> <li>Looking ahead, Nomura expects positive growth to resume again shortly.</li> <li>\"Investors are looking through the somewhat mushy week-over-week comparison and ahead to easier comparisons in 2H19, as well as a gradual improvement in the VIP growth rate as an improving Chinese economy lifts demand for Macau gaming,\" notes analyst Harry Curtis.</li> <li>He notes that EBITDA multiples are below their respective averages for Buy-rated Melco Resorts Entertainment (<a href='https://seekingalpha.com/symbol/MLCO' title='Melco Resorts & Entertainment Limited'>MLCO</a> <font color='red'>-1.2%</font>), MGM Resorts (<a href='https://seekingalpha.com/symbol/MGM' title='MGM Resorts International'>MGM</a> <font color='red'>-1.5%</font>) and Wynn Resorts (<a href='https://seekingalpha.com/symbol/WYNN' title='Wynn Resorts, Limited'>WYNN</a> <font color='red'>-2.2%</font>). Nomura sticks with a positive view on all three casino stocks.</li> </ul><div class=\"tiny-share-widget\" data-id=\"3450702\" data-linked=\"Nomura expects Macau sector to return to positive growth\" data-tweet=\"$MLCO $MGM $WYNN - Nomura expects Macau sector to return to positive growth https://seekingalpha.com/news/3450702-nomura-expects-macau-sector-to-return-to-positive-growth?source=tweet\" data-url=\"https://seekingalpha.com/news/3450702-nomura-expects-macau-sector-to-return-to-positive-growth\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 11:08 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>6&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3450696\" data-ts=\"1555340787\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/CNAT\" target=\"_blank\">CNAT</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3450696-conatus-down-27-on-second-failed-emricasan-study\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Conatus down 27% on second failed emricasan study</a></h4><ul><li>Conatus Pharmaceuticals (<a href='https://seekingalpha.com/symbol/CNAT' title='Conatus Pharmaceuticals Inc.'>CNAT</a> <font color=\"red\">-27.2%</font>) slumps on double normal volume in reaction to <a href=\"https://seekingalpha.com/pr/17476077-conatus-late-breaker-oral-presentation-easl-meeting-details-results-encore-ph-phase-2b\" target=\"_blank\">results </a>from a Phase 2 clinical trial, <a href=\"https://clinicaltrials.gov/ct2/show/NCT02960204?spons=conatus&amp;phase=1&amp;rank=2\" target=\"_blank\">ENCORE-PH</a>, evaluating emricasan in NASH patients with cirrhosis and severe portal hypertension. The data were presented at The International Liver Congress in Vienna.</li><li>Emricasan failed to sufficiently separate from placebo in terms of the mean change from baseline to week 24 in hepatic venous pressure gradient &#40;HVPG&#41;, the primary endpoint (first <a href=\"https://seekingalpha.com/news/3414820-conatus-pharmas-emricasan-flunks-mid-stage-nash-study-shares-62-percent-premarket\" target=\"_blank\">announced</a> in December 2018).</li><li>On the safety front, 79 - 88% of patients receiving 5 mg , 25 mg or 50 mg of emricasan experienced a drug-related adverse event compared to 82% for placebo. The most common were peripheral edema (8 - 15% depending on the dose), nausea (9 - 12%) and urinary tract infection (8 - 15%).</li><li>Shares plummeted over <font color=\"red\">50%</font> in late March when the company <a href=\"https://seekingalpha.com/news/3445040-conatus-pharmas-emricasan-flunks-mid-stage-nash-study-shares-54-percent-premarket\" target=\"_blank\">announced </a>that its ENCORE-HF study failed.</li></ul><div class=\"tiny-share-widget\" data-id=\"3450696\" data-linked=\"Conatus down 27% on second failed emricasan study\" data-tweet=\"$CNAT - Conatus down 27% on second failed emricasan study https://seekingalpha.com/news/3450696-conatus-down-27-on-second-failed-emricasan-study?source=tweet\" data-url=\"https://seekingalpha.com/news/3450696-conatus-down-27-on-second-failed-emricasan-study\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 11:06 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>43&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3450695\" data-ts=\"1555340591\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/\" target=\"_blank\"></a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3450695-cellcomplus-8_3-on-early-loan-repayment\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Cellcom +8.3% on early loan repayment</a></h4><ul>   <li>Cellcom Israel (NYSE:<a href='https://seekingalpha.com/symbol/CEL' title='Cellcom Israel Ltd.'>CEL</a>) is <font color=\"green\">up 8.3%</font> in this morning's NYSE action after the company announced <a href=\"https://seekingalpha.com/pr/17475759-cellcom-israel-announces-early-repayment-bank-loan\" target=\"_blank\">early repayment</a> of a bank loan.</li>    <li>The company repaid a loan of 112M shekels (about $31.45M) that was provided to the company in December 2016</li>    <li>The loan was one of Cellcom's more expensive and shorter-duration loans, it says, and early repayment will allow for saving about 9M shekels in interest expense.</li>    <li>Also higher today: rival Partner Communications (<a href=\"http://seekingalpha.com/symbol/PTNR\" target=\"_blank\">PTNR</a> <font color=\"green\">+3.9%</font>).</li>  </ul><div class=\"tiny-share-widget\" data-id=\"3450695\" data-linked=\"Cellcom +8.3% on early loan repayment\" data-tweet=\"$CEL $PTNR - Cellcom +8.3% on early loan repayment https://seekingalpha.com/news/3450695-cellcomplus-8_3-on-early-loan-repayment?source=tweet\" data-url=\"https://seekingalpha.com/news/3450695-cellcomplus-8_3-on-early-loan-repayment\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 11:03 AM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3450693\" data-ts=\"1555340537\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/\" target=\"_blank\"></a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3450693-fibrocell-science-leads-healthcare-gainers-conatus-pharmaceuticals-and-aphria-among-losers\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Fibrocell Science leads healthcare gainers; Conatus Pharmaceuticals and Aphria among the losers</a></h4><ul><li><b>Gainers: </b>Fibrocell Science (NASDAQ:<a href='https://seekingalpha.com/symbol/FCSC' title='Fibrocell Science, Inc.'>FCSC</a>) <font color=\"green\">+46%</font>. Bio-Path Holdings (NASDAQ:<a href='https://seekingalpha.com/symbol/BPTH' title='Bio-Path Holdings, Inc.'>BPTH</a>) <font color=\"green\">+45%</font>. Conformis (NASDAQ:<a href='https://seekingalpha.com/symbol/CFMS' title='Conformis, Inc.'>CFMS</a>) <font color=\"green\">+9%</font>. Catalent (NYSE:<a href='https://seekingalpha.com/symbol/CTLT' title='Catalent, Inc.'>CTLT</a>) <font color=\"green\">+8%</font>. electroCore (NASDAQ:<a href='https://seekingalpha.com/symbol/ECOR' title='electroCore, Inc.'>ECOR</a>) <font color=\"green\">+7%</font>.</li><li><b>Losers: </b>Conatus Pharmaceuticals (NASDAQ:<a href='https://seekingalpha.com/symbol/CNAT' title='Conatus Pharmaceuticals Inc.'>CNAT</a>) <font color=\"red\">-27%</font>. Assembly Biosciences (NASDAQ:<a href='https://seekingalpha.com/symbol/ASMB' title='Assembly Biosciences, Inc.'>ASMB</a>) <font color=\"red\">-17%</font>. Aphria (NYSE:<a href='https://seekingalpha.com/symbol/APHA' title='Aphria Inc.'>APHA</a>) <font color=\"red\">-13%</font>. Kitov Pharma (NASDAQ:<a href='https://seekingalpha.com/symbol/KTOV' title='Kitov Pharma Ltd'>KTOV</a>) <font color=\"red\">-13%</font>. Vaccinex (NASDAQ:<a href='https://seekingalpha.com/symbol/VCNX' title='Vaccinex, Inc.'>VCNX</a>) <font color=\"red\">-13%</font>.</li></ul><div class=\"tiny-share-widget\" data-id=\"3450693\" data-linked=\"Fibrocell Science leads healthcare gainers; Conatus Pharmaceuticals and Aphria among the losers\" data-tweet=\"$FCSC $BPTH $CFMS - Fibrocell Science leads healthcare gainers; Conatus Pharmaceuticals and Aphria among the losers https://seekingalpha.com/news/3450693-fibrocell-science-leads-healthcare-gainers-conatus-pharmaceuticals-and-aphria-among-losers?source=tweet\" data-url=\"https://seekingalpha.com/news/3450693-fibrocell-science-leads-healthcare-gainers-conatus-pharmaceuticals-and-aphria-among-losers\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 11:02 AM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3450687\" data-ts=\"1555339849\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/TEAM\" target=\"_blank\">TEAM</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3450687-atlassianplus-1_5-on-bullish-oppenheimer-note\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Atlassian +1.5% on bullish Oppenheimer note</a></h4><ul><li>Oppenheimer says it's increasingly confident in Atlassian's (NASDAQ:<a href='https://seekingalpha.com/symbol/TEAM' title='Atlassian Corporation Plc'>TEAM</a>) long-term growth after last week's investor session.</li><li>The firm cites customer dynamics, the growing platform value and partner ecosystem, and product expansion opportunities.</li><li>Oppenheimer maintains an Outperform rating on TEAM.</li><li>Atlassian shares are<font color=\"green\"> </font><font color=\"green\">up 1.5%</font> to $114.42.</li></ul><div class=\"tiny-share-widget\" data-id=\"3450687\" data-linked=\"Atlassian +1.5% on bullish Oppenheimer note\" data-tweet=\"$TEAM - Atlassian +1.5% on bullish Oppenheimer note https://seekingalpha.com/news/3450687-atlassianplus-1_5-on-bullish-oppenheimer-note?source=tweet\" data-url=\"https://seekingalpha.com/news/3450687-atlassianplus-1_5-on-bullish-oppenheimer-note\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 10:50 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>1&nbsp;<span class='comments-number'>Comment</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3450686\" data-ts=\"1555339728\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/WTW\" target=\"_blank\">WTW</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3450686-wwplus-12-after-morgan-stanley-points-to-positive-data\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">WW +12% after Morgan Stanley points to positive data</a></h4><ul> <li>Morgan Stanley calls out improving subscriber trends at WW International (<a href='https://seekingalpha.com/symbol/WTW' title='Weight Watchers International, Inc.'>WTW</a> <font color='green'>+10.6%</font>) based off of download tracking data.</li> <li>The positive MS note has shares cutting into the 40% drop over the last four weeks amid concerns over WW subscriber growth.</li> <li>Analysts at Morgan Stanley have Weight Watchers (WW's old name) lined up at Equal-weight, which appears to be the comfort zone for Wall Street (<a href=\"https://seekingalpha.com/symbol/WTW/earnings/analyst_ratings\" target=\"_blank\">2 Buy-equivalent ratings, 10 Hold-equivalent ratings, 2 Sell-equivalent ratings</a>). The average <a href=\"https://seekingalpha.com/symbol/WTW?s=wtw\" target=\"_blank\">author rating</a> on Seeking Alpha on Weight Watchers is 3.67 (closer to the bullish level of 4.0 than the neutral level of 3.0).</li> </ul><div class=\"tiny-share-widget\" data-id=\"3450686\" data-linked=\"WW +12% after Morgan Stanley points to positive data\" data-tweet=\"$WTW $WW - WW +12% after Morgan Stanley points to positive data https://seekingalpha.com/news/3450686-wwplus-12-after-morgan-stanley-points-to-positive-data?source=tweet\" data-url=\"https://seekingalpha.com/news/3450686-wwplus-12-after-morgan-stanley-points-to-positive-data\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 10:48 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>2&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3450680\" data-ts=\"1555339441\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/GNFT\" target=\"_blank\">GNFT</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3450680-genfit-up-4-on-new-elafibranor-data-in-pbc\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Genfit up 4% on new elafibranor data in PBC</a></h4><ul><li>Genfit (<a href='https://seekingalpha.com/symbol/GNFT' title='Genfit SA'>GNFT</a> <font color=\"green\">+3.5%</font>) is up on below-average volume in reaction to <a href=\"https://seekingalpha.com/pr/17475730-genfit-genfit-present-additional-data-positive-phase-2-clinical-trial-evaluating-elafibranor\" target=\"_blank\">additional data</a> from a Phase 2 clinical trial evaluating lead drug elafibranor in patients with primary biliary cholangitis &#40;PBC&#41;. The results were presented at The International Liver Congress in Vienna.</li><li>Patients receiving the 80 mg and 120 mg doses experienced reductions in mean alkaline phosphatase &#40;ALP&#41; of 48% and 41%, respectively, compared to a 3% increase for placebo (elevated ALP is a biomarker for liver disease).</li><li>Patients in the treatment groups also showed improvements in other PBC markers, including the enzyme GGT, total cholesterol, low-density lipoprotein and triglycerides.</li><li>The company expects to launch a Phase 3 study in PBC this year. A Phase 3 in NASH is underway.</li></ul><div class=\"tiny-share-widget\" data-id=\"3450680\" data-linked=\"Genfit up 4% on new elafibranor data in PBC\" data-tweet=\"$GNFT - Genfit up 4% on new elafibranor data in PBC https://seekingalpha.com/news/3450680-genfit-up-4-on-new-elafibranor-data-in-pbc?source=tweet\" data-url=\"https://seekingalpha.com/news/3450680-genfit-up-4-on-new-elafibranor-data-in-pbc\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 10:44 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>6&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3450683\" data-ts=\"1555339272\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/BABA\" target=\"_blank\">BABA</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3450683-china-names-lower-on-msci-delay\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">China names lower on MSCI delay</a></h4><ul><li>The transition of the MSCI All China Indexes to the MSCI China All Shares Indexes was originally scheduled for June 1, but <a href=\"https://www.caixinglobal.com/2019-04-15/msci-postpones-china-index-transition-for-nearly-six-months-101404443.html\" target=\"_blank\">that's been shifted back</a> to November 26.</li><li>The change is being made to eliminate the multiple methodologies upon which MSCI covers China-related shares. It would boost the weighting of A-shares in MSCI indexes to 20% from 5%.</li><li>Names in the red: Alibaba (<a href='https://seekingalpha.com/symbol/BABA' title='Alibaba Group Holding Limited'>BABA</a> <font color='red'>-3.2%</font>), Baidu (<a href='https://seekingalpha.com/symbol/BIDU' title='Baidu, Inc.'>BIDU</a> <font color='red'>-2.9%</font>), JD.com (<a href='https://seekingalpha.com/symbol/JD' title='JD.com, Inc.'>JD</a> <font color='red'>-4.3%</font>), Bilibili (<a href='https://seekingalpha.com/symbol/BILI' title='Bilibili Inc.'>BILI</a> <font color='red'>-5.9%</font>).</li><li>The Xrackers Harvest CSI 300 China A-Shares ETF (<a href='https://seekingalpha.com/symbol/ASHR' title='Deutsche X-trackers Harvest CSI 300 China A-Shares ETF'>ASHR</a> <font color='red'>-2.4%</font>)</li><li>ETFs: <a href='https://seekingalpha.com/symbol/FXI' title='iShares China Large-Cap ETF'>FXI</a>, <a href='https://seekingalpha.com/symbol/ASHR' title='Deutsche X-trackers Harvest CSI 300 China A-Shares ETF'>ASHR</a>, <a href='https://seekingalpha.com/symbol/YINN' title='Direxion Daily FTSE China Bull 3x Shares ETF'>YINN</a>, <a href='https://seekingalpha.com/symbol/CAF' title='Morgan Stanley China A Share Fund'>CAF</a>, <a href='https://seekingalpha.com/symbol/YANG' title='Direxion Daily FTSE China Bear 3x Shares ETF'>YANG</a>, <a href='https://seekingalpha.com/symbol/MCHI' title='iShares MSCI China ETF'>MCHI</a>, <a href='https://seekingalpha.com/symbol/GXC' title='SPDR S&P China ETF'>GXC</a>, <a href='https://seekingalpha.com/symbol/FXP' title='ProShares UltraShort FTSE China 25 ETF'>FXP</a>, <a href='https://seekingalpha.com/symbol/PGJ' title='Invesco Golden Dragon China Portfolio ETF'>PGJ</a>, <a href='https://seekingalpha.com/symbol/CN' title='Deutsche X-trackers Harvest MSCI All China Equity ETF'>CN</a>, <a href='https://seekingalpha.com/symbol/KBA' title='KraneShares Bosera MSCI China A ETF'>KBA</a>, <a href='https://seekingalpha.com/symbol/TDF' title='Templeton Dragon Fund'>TDF</a>, <a href='https://seekingalpha.com/symbol/PEK' title='VanEck Vectors ChinaAMC CSI 300 ETF'>PEK</a>, <a href='https://seekingalpha.com/symbol/CHN' title='China Fund'>CHN</a>, <a href='https://seekingalpha.com/symbol/CXSE' title='WisdomTree China ex-State-Owned Enterprises ETF'>CXSE</a>, <a href='https://seekingalpha.com/symbol/CHAU' title='Direxion Daily CSI 300 China A Share Bull 2x Shares ETF'>CHAU</a>, <a href='https://seekingalpha.com/symbol/XPP' title='ProShares Ultra FTSE China 25 ETF'>XPP</a>, <a href='https://seekingalpha.com/symbol/CNXT' title='VanEck Vectors ChinaAMC SME-ChiNext ETF'>CNXT</a></li></ul><div class=\"tiny-share-widget\" data-id=\"3450683\" data-linked=\"China names lower on MSCI delay\" data-tweet=\"$BABA $BIDU $JD - China names lower on MSCI delay https://seekingalpha.com/news/3450683-china-names-lower-on-msci-delay?source=tweet\" data-url=\"https://seekingalpha.com/news/3450683-china-names-lower-on-msci-delay\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 10:41 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>32&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3450682\" data-ts=\"1555339270\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/CISN\" target=\"_blank\">CISN</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3450682-cision-taps-ibm-vet-hr-head\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Cision taps IBM vet as HR head</a></h4><ul><li>Cision (<a href='https://seekingalpha.com/symbol/CISN' title='Cision Ltd.'>CISN</a> <font color='red'>-1.2%</font>) <a href=\"https://seekingalpha.com/pr/17476407-cision-names-susan-steele-chief-human-resources-officer\" target=\"_blank\">names</a> Susan Steele as the new Chief Human Resources Officer.</li><li>Steele previously served as IBM's HR Reinvention Lead for Global Talent and Transformation.</li></ul><div class=\"tiny-share-widget\" data-id=\"3450682\" data-linked=\"Cision taps IBM vet as HR head\" data-tweet=\"$CISN - Cision taps IBM vet as HR head https://seekingalpha.com/news/3450682-cision-taps-ibm-vet-hr-head?source=tweet\" data-url=\"https://seekingalpha.com/news/3450682-cision-taps-ibm-vet-hr-head\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 10:41 AM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3450681\" data-ts=\"1555339142\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/GMVHF\" target=\"_blank\">GMVHF</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3450681-insider-sales-gvc-holdings-scrutinized\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Insider sales at GVC Holdings scrutinized</a></h4><ul> <li>There is some head scratching over a <a href=\"https://www.thetimes.co.uk/edition/business/revealed-gambling-bosses-at-ladbrokes-signed-off-each-others-share-sales-8d76k5b0n\" target=\"_blank\">report</a> that GVC Holdings' (<a href='https://seekingalpha.com/symbol/GMVHF' title='GVC Holdings PLC'>OTCPK:GMVHF</a>) chairman and CEO signed off on each other's large share sales last month</li> <li>The sales were worth £20M and are described by The Times as \"high controversial\" due to the share price movement they caused.</li> <li>GVC hasn't said if either the chairman or CEO sought consent from other directors to sell, but noted the transactions were in adherence to corporate governance proceedings.</li> <li>Shares of GVC are <font color=\"red\">down 1.66%</font> in London.</li> </ul><div class=\"tiny-share-widget\" data-id=\"3450681\" data-linked=\"Insider sales at GVC Holdings scrutinized\" data-tweet=\"$GMVHF - Insider sales at GVC Holdings scrutinized https://seekingalpha.com/news/3450681-insider-sales-gvc-holdings-scrutinized?source=tweet\" data-url=\"https://seekingalpha.com/news/3450681-insider-sales-gvc-holdings-scrutinized\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 10:39 AM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3450679\" data-ts=\"1555338462\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/OXY\" target=\"_blank\">OXY</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3450679-occidental-bid-for-anadarko-hit-mid-70s-chevron-deal-news-cnbc\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Occidental bid for Anadarko hit mid-$70s before Chevron deal news - CNBC</a></h4><ul><li><a href=\"https://www.cnbc.com/2019/04/15/occidental-bid-for-anadarko-reached-mid-70s-per-share-before-chevron-deal-disrupted-talks-sources.html\" target=\"_blank\">Merger talks were ongoing</a> between Occidental Petroleum (<a href='https://seekingalpha.com/symbol/OXY' title='Occidental Petroleum Corporation'>OXY</a> <font color='red'>-3%</font>) and Anadarko Petroleum (<a href='https://seekingalpha.com/symbol/APC' title='Anadarko Petroleum Corporation'>APC</a> <font color='green'>+2%</font>) when Chevron (<a href='https://seekingalpha.com/symbol/CVX' title='Chevron Corporation'>CVX</a> <font color='green'>+0.8%</font>) announced on Friday it would acquire APC for $33B, preventing OXY from potentially improving its offer price, CNBC's David Faber reports.</li><li>OXY's bid had reached the mid-$70s/share and was being structured as a 40% cash deal, and the company was under the impression talks would extend into the weekend with an opportunity to increase its bid, but CVX's deal announcement on Friday cut the talks short, according to the report.</li><li>OXY is considering whether it should take its price to APC shareholders in an unsolicited offer, CNBC says.</li><li><a href=\"https://seekingalpha.com/news/3450312-occidental-bid-70-share-anadarko-cnbc\" target=\"_blank\">Earlier</a>: Occidental had bid more than $70/share for Anadarko - CNBC (Apr. 12)</li></ul><div class=\"tiny-share-widget\" data-id=\"3450679\" data-linked=\"Occidental bid for Anadarko hit mid-$70s before Chevron deal news - CNBC\" data-tweet=\"$OXY $APC $CVX - Occidental bid for Anadarko hit mid-$70s before Chevron deal news - CNBC https://seekingalpha.com/news/3450679-occidental-bid-for-anadarko-hit-mid-70s-chevron-deal-news-cnbc?source=tweet\" data-url=\"https://seekingalpha.com/news/3450679-occidental-bid-for-anadarko-hit-mid-70s-chevron-deal-news-cnbc\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 10:27 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>38&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3450678\" data-ts=\"1555338264\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/\" target=\"_blank\"></a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3450678-piper-apex-legends-leads-to-twitch-triple-for-ea\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Piper: &#39;Apex Legends&#39; leads to Twitch triple for EA</a></h4><ul>   <li>Electronic Arts' (<a href=\"http://seekingalpha.com/symbol/EA\" target=\"_blank\">EA</a> <font color=\"red\">-2.2%</font>) minutes on Twitch more than tripled in Q1 from Q4, Piper Jaffray's Michael Olson notes, thanks to its rollout of hit <i>Apex Legends,</i> which <a href=\"https://seekingalpha.com/news/3431370-ea-rebounds-9_4-percent-praise-gathers-apex-legends\" target=\"_blank\">spurred stock gains in early February</a>.</li>    <li>EA's Twitch viewership rose 281%; among its big rivals, Take-Two (<a href=\"http://seekingalpha.com/symbol/TTWO\" target=\"_blank\">TTWO</a> <font color=\"green\">+1.4%</font>) viewer minutes rose 38% sequentially, and those of Activision Blizzard (<a href=\"http://seekingalpha.com/symbol/ATVI\" target=\"_blank\">ATVI</a> <font color=\"red\">-0.2%</font>) fell 22%, Olson notes. <i>Fortnite</i> (made by Epic Games, backed by Tencent (<a href=\"http://seekingalpha.com/symbol/TCEHY\" target=\"_blank\">TCEHY</a> <font color=\"red\">-1.9%</font>)) still tops the viewer chart but fell for the third quarter in a row.</li>    <li>Also, EA and Respawn announced at the <i>Star Wars</i> Celebration that action-adventure game <i>Star Wars Jedi: Fallen Order</i> will <a href=\"https://seekingalpha.com/pr/17475750-ea-respawn-announce-star-wars-jedi-fallen-order-will-launch-november-15-2019\" target=\"_blank\">launch Nov. 15</a>, just a month before the release of the series' Episode IX film, <i>Star Wars: The Rise of Skywalker.</i></li> </ul><div class=\"tiny-share-widget\" data-id=\"3450678\" data-linked=\"Piper: &#39;Apex Legends&#39; leads to Twitch triple for EA\" data-tweet=\"$EA $TTWO $ATVI - Piper: &#39;Apex Legends&#39; leads to Twitch triple for EA https://seekingalpha.com/news/3450678-piper-apex-legends-leads-to-twitch-triple-for-ea?source=tweet\" data-url=\"https://seekingalpha.com/news/3450678-piper-apex-legends-leads-to-twitch-triple-for-ea\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 10:24 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>7&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3450677\" data-ts=\"1555338227\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/ATAI\" target=\"_blank\">ATAI</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3450677-volatile-trading-on-ata\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Volatile trading on ATA</a></h4><ul> <li>ATA (NASDAQ:<a href='https://seekingalpha.com/symbol/ATAI' title='ATA Inc.'>ATAI</a>) <font color=\"green\">jumps 22.80%</font> to follow on two days of weak trading at the end of last week.</li> <li>Trading on the Chinese education stock is already almost double normal activity at 2.1M shares.</li> <li>ATA has seen a high level of short interest in the past.</li> </ul><div class=\"tiny-share-widget\" data-id=\"3450677\" data-linked=\"Volatile trading on ATA\" data-tweet=\"$ATAI $AACG - Volatile trading on ATA https://seekingalpha.com/news/3450677-volatile-trading-on-ata?source=tweet\" data-url=\"https://seekingalpha.com/news/3450677-volatile-trading-on-ata\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 10:23 AM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3450673\" data-ts=\"1555337875\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/CXDC\" target=\"_blank\">CXDC</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3450673-china-xd-plasticsplus-3-post-q4-results-provides-fy19-guidance\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">China XD Plastics +3% post Q4 results; provides FY19 guidance</a></h4><ul><li>China XD Plastics (<a href='https://seekingalpha.com/symbol/CXDC' title='China XD Plastics Company Limited'>CXDC</a> <font color=\"green\">+3.9%</font>) reported Q4 revenue decrease of 18.2% Y/Y to $349.83M, due to a 19.9% Y/Y decrease in sales volume.</li><li>Q4 Gross margin <font color=\"red\">declined by 360 bps</font> to 17.8%, due to lower sales of higher-end products by Dubai Xinda; operating margin <font color=\"red\">declined by 868 bps</font> to 6.9%.</li><li>EBITDA decreased 53.7% Y/Y to $38.37M; and margin <font color=\"red\">declined by 841 bps</font> to 10.9%.</li><li>Q4 Total operating expenses increased by 53.8% Y/Y to $38.25M; with selling at $2.71M (+148.1% Y/Y); G&amp;A $8.64M (-29.1% Y/Y) and R&amp;D $26.89M (+132.2% Y/Y).</li><li>Total volume shipped was 124,697 metric tons, down 19.9% Y/Y.</li><li>Net cash provided by operating activities YTD was $61.39M, compared to $124.84M a year ago.</li><li>Company has Cash, cash equivalents and restricted cash at end of year of $366.99M, compared to $320.09M a year ago.</li><li><strong>FY19 Guidance:</strong> Revenue $1.3B to $1.6B; Net income $90M to $110M; company expects gross margin to remain stable; and assumes the average exchange rate of the US dollar to RMB at 6.8.</li><li>Previously: <a href=\"https://seekingalpha.com/news/3450577-china-xd-plastics-reports-q4-results\" target=\"_blank\">China XD Plastics reports Q4 results</a> (April 15)</li></ul><div class=\"tiny-share-widget\" data-id=\"3450673\" data-linked=\"China XD Plastics +3% post Q4 results; provides FY19 guidance\" data-tweet=\"$CXDC - China XD Plastics +3% post Q4 results; provides FY19 guidance https://seekingalpha.com/news/3450673-china-xd-plasticsplus-3-post-q4-results-provides-fy19-guidance?source=tweet\" data-url=\"https://seekingalpha.com/news/3450673-china-xd-plasticsplus-3-post-q4-results-provides-fy19-guidance\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 10:17 AM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3450671\" data-ts=\"1555337725\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/ADVM\" target=\"_blank\">ADVM</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3450671-adverum-down-7-on-fda-suspension-of-gene-therapy-trial\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Adverum down 7% on FDA suspension of gene therapy trial</a></h4><ul><li>Adverum Biotechnologies (<a href='https://seekingalpha.com/symbol/ADVM' title='Adverum Biotechnologies, Inc.'>ADVM</a> <font color=\"red\">-7.2%</font>) is down on below-average volume in reaction to its <a href=\"https://seekingalpha.com/pr/17476426-adverum-biotechnologies-provides-clinical-program-update-advmminus-022-gene-therapy-wet-amd\" target=\"_blank\">announcement </a>that the FDA has placed a clinical hold on its Phase 1 study, <a href=\"https://clinicaltrials.gov/ct2/show/NCT03748784?spons=adverum&amp;rank=3\" target=\"_blank\">OPTIC</a>, evaluating gene therapy candidate ADVM-022 in patients with wet age-related macular degeneration (wet AMD) citing the need for additional information related to chemistry, manufacturing and controls &#40;CMC&#41;, including certain requirements on the manufacturing process.</li><li>The company submitted its response last week and expects to resume dosing as soon as allowed, adding that the first cohort of six patients have already been dosed and enrollment is ready to proceed in the second cohort.</li><li><strong>Update</strong>: Shares reversed, now up <font color=\"green\">7%</font>.</li></ul><div class=\"tiny-share-widget\" data-id=\"3450671\" data-linked=\"Adverum down 7% on FDA suspension of gene therapy trial\" data-tweet=\"$ADVM - Adverum down 7% on FDA suspension of gene therapy trial https://seekingalpha.com/news/3450671-adverum-down-7-on-fda-suspension-of-gene-therapy-trial?source=tweet\" data-url=\"https://seekingalpha.com/news/3450671-adverum-down-7-on-fda-suspension-of-gene-therapy-trial\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 10:15 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>6&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3450670\" data-ts=\"1555337576\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/VEC\" target=\"_blank\">VEC</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3450670-vectrusplus-32-on-four-u-s-military-orders\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Vectrus +32% on four U.S. military orders</a></h4><ul><li>Vectrus (NYSE:<a href='https://seekingalpha.com/symbol/VEC' title='Vectrus, Inc.'>VEC</a>) <font color=\"green\">gains 32.2%</font> after <a href=\"https://seekingalpha.com/pr/17475754-vectrus-awarded-position-logistics-civil-augmentation-program-logcap-v-indefinite-delivery\" target=\"_blank\">announcing</a> four Indefinite Delivery Indefinite Quantity task orders for Logistics Civil Augmentation Program V support services to the U.S. Military worldwide.</li><li>Each contract has a five-year ordering period and options for five additional one-year periods.</li><li>The ceiling price for the entire batch of orders is $82B, but that covers all accepted RFPs and not just Vectrus.</li></ul><div class=\"tiny-share-widget\" data-id=\"3450670\" data-linked=\"Vectrus +32% on four U.S. military orders\" data-tweet=\"$VEC - Vectrus +32% on four U.S. military orders https://seekingalpha.com/news/3450670-vectrusplus-32-on-four-u-s-military-orders?source=tweet\" data-url=\"https://seekingalpha.com/news/3450670-vectrusplus-32-on-four-u-s-military-orders\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 10:12 AM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3450662\" data-ts=\"1555336745\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/ALNY\" target=\"_blank\">ALNY</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3450662-alnylam-launches-late-stage-study-of-lumasiran-in-ph1\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Alnylam launches late-stage study of lumasiran in PH1</a></h4><ul><li>Alnylam Pharmaceuticals (<a href='https://seekingalpha.com/symbol/ALNY' title='Alnylam Pharmaceuticals, Inc.'>ALNY</a> <font color=\"red\">-0.2%</font>) <a href=\"https://seekingalpha.com/pr/17475840-alnylam-initiates-illuminate-b-phase-3-pediatric-study-lumasiran-treatment-primary\" target=\"_blank\">initiates </a>an open-label Phase 3 clinical trial, <a href=\"https://clinicaltrials.gov/ct2/show/NCT03905694?spons=alnylam&amp;phase=2&amp;rank=1\" target=\"_blank\">ILLUMINATE-B</a>, evaluating lumasiran in infants and young children with <a href=\"https://rarediseases.info.nih.gov/diseases/2835/primary-hyperoxaluria-type-1\" target=\"_blank\">primary hyperoxaluria type 1</a> (PH1), a rare inherited disorder characterized by kidney and bladder stones caused by the buildup a compound called oxalate in the kidneys and urinary tract.</li><li>The primary endpoint of the eight-subject study is the percent reduction in urinary oxalate from baseline at month 6. The estimated primary completion date is March 2020.</li><li>Lumasiran is an RNAi therapeutic designed to lower oxalate by reducing the levels of an enzyme called glycolate oxidase in the liver which depletes the substrate necessary for oxalate production. It has accelerated review status in the U.S. and Europe.</li><li>Updated results from a Phase 1/2 study showed a 72% average maximum reduction from baseline in urinary oxalate excretion. The average reduction from baseline at day 85 was 69%.</li></ul><div class=\"tiny-share-widget\" data-id=\"3450662\" data-linked=\"Alnylam launches late-stage study of lumasiran in PH1\" data-tweet=\"$ALNY - Alnylam launches late-stage study of lumasiran in PH1 https://seekingalpha.com/news/3450662-alnylam-launches-late-stage-study-of-lumasiran-in-ph1?source=tweet\" data-url=\"https://seekingalpha.com/news/3450662-alnylam-launches-late-stage-study-of-lumasiran-in-ph1\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  9:59 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>1&nbsp;<span class='comments-number'>Comment</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3450659\" data-ts=\"1555336344\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/\" target=\"_blank\"></a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3450659-golf-stocks-rally-after-tiger-woods-victory\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Golf stocks rally after Tiger Woods victory</a></h4><ul> <li>Shares of Callaway Golf (NYSE:<a href='https://seekingalpha.com/symbol/ELY' title='Callaway Golf Company'>ELY</a>) are <font color=\"green\">up 3.55%</font> and Acushnet Holdings (NYSE:<a href='https://seekingalpha.com/symbol/GOLF' title='Acushnet Holdings Corp.'>GOLF</a>) is <font color=\"green\">2.05% higher</font> in the wake of Tiger Woods win in the Masters.</li> <li>The Woods victory dominated social media yesterday and is thought to have raised the profile of golf just ahead of the spring/summer season.</li> <li>Nike (NYSE:<a href='https://seekingalpha.com/symbol/NKE' title='NIKE, Inc.'>NKE</a>) is <font color=\"green\">up 1.05%</font> to outpace broad market averages and lead the Dow 30 on the day, with some investors betting the company will see increased interest in its large line of Tiger Woods golf apparel.</li><li>Previously: <a href=\"https://seekingalpha.com/news/3450504-win-tiger-win-nike\" target=\"_blank\">A win for Tiger is a win for Nike</a> (April 15)</li><li>Previously: <a href=\"https://seekingalpha.com/news/3450527-tiger-woods-win-impacts-sportsbooks\" target=\"_blank\">Tiger Woods win impacts sportsbooks</a> (April 15)</li>  </ul><div class=\"tiny-share-widget\" data-id=\"3450659\" data-linked=\"Golf stocks rally after Tiger Woods victory\" data-tweet=\"$ELY $GOLF $NKE - Golf stocks rally after Tiger Woods victory https://seekingalpha.com/news/3450659-golf-stocks-rally-after-tiger-woods-victory?source=tweet\" data-url=\"https://seekingalpha.com/news/3450659-golf-stocks-rally-after-tiger-woods-victory\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  9:52 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>12&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3450656\" data-ts=\"1555336112\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/MTCH\" target=\"_blank\">MTCH</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3450656-matchplus-1_2-on-new-asia-gms-hiring-spree\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Match +1.2% on new Asia GMs, hiring spree</a></h4><ul><li>Match Group (NASDAQ:<a href='https://seekingalpha.com/symbol/MTCH' title='Match Group, Inc.'>MTCH</a>) <a href=\"https://seekingalpha.com/pr/17476509-match-group-restructures-leadership-accelerate-international-growth\" target=\"_blank\">appoints</a> three GMs in Asia: Junya Ishibashi for Japan and Taiwan, Taru Kapoor for India, and Lyla Seo for South Korea and Southeast Asia.</li><li>Alexandre Lubot will remain CEO of Match Group EMEA &amp; APAC. Elisabeth Peyraube will take on the new role of COO and CFO of EMEA &amp; APAC.</li><li>The company says nearly 50% of its revenue comes from outside the U.S. and Canada and aims to have a quarter of the revenue come from Asia within five years.</li><li>Over the weekend, <a href=\"https://www.ft.com/content/31bcc2a6-5e41-11e9-b285-3acd5d43599e\" target=\"_blank\">Financial Times </a>reported on MTCH's Asia \"hiring spree\" with plans to increase the headcount by 40% this year.</li><li>Match shares are <font color=\"green\">up 1.2%</font> to $57.87.</li></ul><div class=\"tiny-share-widget\" data-id=\"3450656\" data-linked=\"Match +1.2% on new Asia GMs, hiring spree\" data-tweet=\"$MTCH - Match +1.2% on new Asia GMs, hiring spree https://seekingalpha.com/news/3450656-matchplus-1_2-on-new-asia-gms-hiring-spree?source=tweet\" data-url=\"https://seekingalpha.com/news/3450656-matchplus-1_2-on-new-asia-gms-hiring-spree\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  9:48 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>8&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3450650\" data-ts=\"1555335516\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/CIEN\" target=\"_blank\">CIEN</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3450650-cienaplus-2-northland-turns-bullish\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Ciena +2% as Northland turns bullish</a></h4><ul><li>Northland Securities upgrades Ciena (NYSE:<a href='https://seekingalpha.com/symbol/CIEN' title='Ciena Corporation'>CIEN</a>) from Market Perform to Outperform and lifts the target from $34 to $42, implying an 11% upside.</li><li>Last month, Ciena <a href=\"https://seekingalpha.com/news/3439753-ciena-plus-1_4-percent-q1-beats-three-year-targets\" target=\"_blank\">reported</a> Q1 beats and its three-year growth targets.</li><li>Ciena shares are <font color=\"green\">up 2.1%</font> to $38.80.</li></ul><div class=\"tiny-share-widget\" data-id=\"3450650\" data-linked=\"Ciena +2% as Northland turns bullish\" data-tweet=\"$CIEN - Ciena +2% as Northland turns bullish https://seekingalpha.com/news/3450650-cienaplus-2-northland-turns-bullish?source=tweet\" data-url=\"https://seekingalpha.com/news/3450650-cienaplus-2-northland-turns-bullish\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  9:38 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>3&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3450629\" data-ts=\"1555335285\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/ASMB\" target=\"_blank\">ASMB</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3450629-assembly-bio-down-25-on-mid-stage-data-on-hbv-candidate\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Assembly Bio down 25% on mid-stage data on HBV candidate</a></h4><ul><li>Thinly traded micro cap Assembly Biosciences (<a href='https://seekingalpha.com/symbol/ASMB' title='Assembly Biosciences, Inc.'>ASMB</a> <font color=\"red\">-25.3%</font>) is down out the gate this morning on the heels of <a href=\"https://seekingalpha.com/pr/17475745-assembly-biosciences-presents-interim-data-two-phase-2a-studies-abi-h0731-hbv-infected\" target=\"_blank\">interim data</a> from two Phase 2a clinical trials evaluating antiviral candidate ABI-H0731 (731) in patients with hepatitis B virus &#40;HBV&#41; infection. The results were presented at The International Liver Congress in Vienna.</li><li>Quest Clinical Research's Dr. Jacob Lalezari says, \"The data we have seen thus far are directionally correct and decreases in HBeAg and HBsAg have been observed in some individuals in both studies,\" a less-than-resounding assessment which appears to have dampened investor enthusiasm.</li><li>In the first trial, Study 201, 60% of subjects with quantifiable HBV RNA at entry who received the combination of 731 and nucleotide/side therapy (Nuc) experienced reductions in RNA below the limit of quantitation &#40;LOQ&#41; by week 16 compared to 0% for Nuc alone. The levels of HBV DNA in the blood was consistently detectable at the LOQ in all patients in Nuc monotherapy while \"several subjects\" on the combo regimen showed further reductions in HBV DNA to below the limit of detection by PCR assay (2-5 copies).</li><li>In the second trial, Study 202, the combination of 731 and entecavir appeared to be only incrementally better than entecavir alone in terms of HBV DNA levels. The separation was more significant related to RNA levels.</li></ul><div class=\"tiny-share-widget\" data-id=\"3450629\" data-linked=\"Assembly Bio down 25% on mid-stage data on HBV candidate\" data-tweet=\"$ASMB - Assembly Bio down 25% on mid-stage data on HBV candidate https://seekingalpha.com/news/3450629-assembly-bio-down-25-on-mid-stage-data-on-hbv-candidate?source=tweet\" data-url=\"https://seekingalpha.com/news/3450629-assembly-bio-down-25-on-mid-stage-data-on-hbv-candidate\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  9:34 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>2&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3450643\" data-ts=\"1555334959\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/\" target=\"_blank\"></a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3450643-applied-optominus-3_4-rosenblatt-warns-of-facebook-100g-share-loss\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Applied Opto -3.4% as Rosenblatt warns of Facebook 100G share loss</a></h4><ul>   <li>Applied Optoelectronics (NASDAQ:<a href='https://seekingalpha.com/symbol/AAOI' title='Applied Optoelectronics, Inc.'>AAOI</a>) is <font color=\"red\">3.4% lower</font> premarket as bearish Rosenblatt warns that the company may have lost all of its 100G share at Facebook to rival Finisar (NASDAQ:<a href='https://seekingalpha.com/symbol/FNSR' title='Finisar Corporation'>FNSR</a>).</li>    <li>That would point to a 20-30% sequential decline in total revenue in Q2, analyst Jun Zhang writes. There's not much change in the offing for total 100G orders from Google, Facebook or Microsoft, according to the note, and Google and Amazon will be focusing on 400G upgrades (benefiting Lumentum (NASDAQ:<a href='https://seekingalpha.com/symbol/LITE' title='Lumentum Holdings Inc.'>LITE</a>) in laser content growth, and Inphi (NYSE:<a href='https://seekingalpha.com/symbol/IPHI' title='Inphi Corporation'>IPHI</a>) outpacing Broadcom (NASDAQ:<a href='https://seekingalpha.com/symbol/AVGO' title='Broadcom Inc.'>AVGO</a>) in share of 400G DSP). (h/t Bloomberg)</li>    <li>Also premarket: Finisar (<a href='https://seekingalpha.com/symbol/FNSR' title='Finisar Corporation'>FNSR</a>) <font color=\"red\">-0.4%</font>; Lumentum (<a href='https://seekingalpha.com/symbol/LITE' title='Lumentum Holdings Inc.'>LITE</a>) <font color=\"red\">-0.1%</font>; Inphi (<a href='https://seekingalpha.com/symbol/IPHI' title='Inphi Corporation'>IPHI</a>) <font color=\"green\">+1.2%</font>; Broadcom (<a href='https://seekingalpha.com/symbol/AVGO' title='Broadcom Inc.'>AVGO</a>) <font color=\"green\">+0.3%</font>.</li> </ul><div class=\"tiny-share-widget\" data-id=\"3450643\" data-linked=\"Applied Opto -3.4% as Rosenblatt warns of Facebook 100G share loss\" data-tweet=\"$AAOI $FNSR $LITE - Applied Opto -3.4% as Rosenblatt warns of Facebook 100G share loss https://seekingalpha.com/news/3450643-applied-optominus-3_4-rosenblatt-warns-of-facebook-100g-share-loss?source=tweet\" data-url=\"https://seekingalpha.com/news/3450643-applied-optominus-3_4-rosenblatt-warns-of-facebook-100g-share-loss\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  9:29 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>10&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3450641\" data-ts=\"1555334865\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/\" target=\"_blank\"></a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3450641-gogo-amrs-among-premarket-gainers\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">GOGO, AMRS among premarket gainers</a></h4><ul><li>Fibrocell Science (NASDAQ:<a href='https://seekingalpha.com/symbol/FCSC' title='Fibrocell Science, Inc.'>FCSC</a>) <font color=\"green\">+56%</font> on Castle Creek <a href=\"https://seekingalpha.com/news/3450615-fibrocell-51-percent-premarket-castle-creek-collaboration\" target=\"_blank\">collaboration</a>.</li><li>Bio-Path Holdings (NASDAQ:<a href='https://seekingalpha.com/symbol/BPTH' title='Bio-Path Holdings, Inc.'>BPTH</a>) <font color=\"green\">+38%</font> on <a href=\"https://seekingalpha.com/news/3450596-bio-path-37-percent-premarket-withdrawal-stock-offering\" target=\"_blank\">withdrawal</a> of stock offering.</li><li>Electronics for Imaging (NASDAQ:<a href='https://seekingalpha.com/symbol/EFII' title='Electronics for Imaging, Inc.'>EFII</a>) <font color=\"green\">+26%</font> on being <a href=\"https://seekingalpha.com/news/3450607-electronics-imaging-acquired-1_7b\" target=\"_blank\">acquired</a> for $1.7B.</li><li>Phunware (NASDAQ:<a href='https://seekingalpha.com/symbol/PHUN' title='Phunware Inc.'>PHUN</a>) <font color=\"green\">+22%</font> on <a href=\"https://seekingalpha.com/pr/17476060-phunware-enters-agreement-endpoint-ip-monetize-mobile-patent-portfolio\" target=\"_blank\">announcing</a> a commercial agreement with Endpoint IP.</li><li>Advanced Disposal Services (NYSE:<a href='https://seekingalpha.com/symbol/ADSW' title='Advanced Disposal Services, Inc.'>ADSW</a>) <font color=\"green\">+19%</font> on being <a href=\"https://seekingalpha.com/news/3450544-waste-management-5b-deal-advanced-disposal\" target=\"_blank\">acquired</a> by Waste Management.</li><li>Gogo (NASDAQ:<a href='https://seekingalpha.com/symbol/GOGO' title='Gogo Inc.'>GOGO</a>) <font color=\"green\">+17%</font> on <a href=\"https://seekingalpha.com/news/3450564-gogo-announces-prelim-q1-900m-note-offering\" target=\"_blank\">announcing</a> prelim Q1, $900M note offering</li><li>ATA (NASDAQ:<a href='https://seekingalpha.com/symbol/ATAI' title='ATA Inc.'>ATAI</a>) <font color=\"green\">+9%</font>.</li><li>Amyris (NASDAQ:<a href='https://seekingalpha.com/symbol/AMRS' title='Amyris, Inc.'>AMRS</a>) <font color=\"green\">+8%</font> on <a href=\"https://seekingalpha.com/pr/17476304-amyris-provides-update-resolution-april-2019-convertible-note-maturity\" target=\"_blank\">update</a> on resolution of April 2019 convertible note maturity.</li><li>Pulmatrix (NASDAQ:<a href='https://seekingalpha.com/symbol/PULM' title='Pulmatrix, Inc.'>PULM</a>) <font color=\"green\">+7%</font> on <a href=\"https://seekingalpha.com/pr/17476384-pulmatrix-cipla-technologies-llc-enter-definitive-agreement-development-commercialization\" target=\"_blank\">entering</a> into definitive agreement for the development and commercialization of Pulmazole with Cipla Technologies LLC.</li><li>Safe-T Group (NASDAQ:<a href='https://seekingalpha.com/symbol/SFET' title='Safe-T Group Ltd'>SFET</a>) <font color=\"green\">+6%</font> on <a href=\"https://seekingalpha.com/pr/17475802-safe-t-introduces-user-entity-behavior-analytics-capabilities-world-software-defined\" target=\"_blank\">launching</a> of its user and web-based anomaly detection product.</li><li>Titan Pharmaceuticals (NASDAQ:<a href='https://seekingalpha.com/symbol/TTNP' title='Titan Pharmaceuticals, Inc.'>TTNP</a>) <font color=\"green\">+6%</font>.</li><li>Axsome Therapeutics (NASDAQ:<a href='https://seekingalpha.com/symbol/AXSM' title='Axsome Therapeutics, Inc.'>AXSM</a>) <font color=\"green\">+6%</font> as AXS-05 <a href=\"https://seekingalpha.com/news/3450552-axsomes-axsminus-05-meets-primary-endpoint-mid-stage-trial-smoking-cessation\" target=\"_blank\">meets</a> primary endpoint in mid-stage trial in smoking cessation.</li></ul><div class=\"tiny-share-widget\" data-id=\"3450641\" data-linked=\"GOGO, AMRS among premarket gainers\" data-tweet=\"$FCSC $BPTH $EFII - GOGO, AMRS among premarket gainers https://seekingalpha.com/news/3450641-gogo-amrs-among-premarket-gainers?source=tweet\" data-url=\"https://seekingalpha.com/news/3450641-gogo-amrs-among-premarket-gainers\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  9:27 AM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3450635\" data-ts=\"1555334571\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/TGTX\" target=\"_blank\">TGTX</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3450635-tg-therapeutics-receives-odd-for-umbralisib\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">TG Therapeutics receives ODD for umbralisib</a></h4><ul> <li>The FDA has <a href=\"https://seekingalpha.com/pr/17476083-tg-therapeutics-receives-orphan-drug-designation-umbralisib-u-s-food-drug-administration\" target=\"_blank\">granted</a> orphan drug designation to TG Therapeutics' (NASDAQ:<a href='https://seekingalpha.com/symbol/TGTX' title='TG Therapeutics, Inc.'>TGTX</a>) phosphoinositide-3-kinase (PI3K) delta inhibitor, umbralisib (TGR-1202), for the treatment of patients with all three types of marginal zone lymphoma &#40;MZL&#41;: nodal, extranodal, and splenic MZL.</li><li>Among the benefits of Orphan Drug status in the U.S. is a seven-year period of market exclusivity for the indication, if approved.</li>   <li>The MZL cohort of the UNITY-NHL trial is currently evaluating the safety and efficacy of single agent umbralisib in patients with MZL who have received at least one prior anti-CD20 regimen.</li><li>Shares are up <font color=\"green\">2%</font> premarket.</li>    </ul><div class=\"tiny-share-widget\" data-id=\"3450635\" data-linked=\"TG Therapeutics receives ODD for umbralisib\" data-tweet=\"$TGTX - TG Therapeutics receives ODD for umbralisib https://seekingalpha.com/news/3450635-tg-therapeutics-receives-odd-for-umbralisib?source=tweet\" data-url=\"https://seekingalpha.com/news/3450635-tg-therapeutics-receives-odd-for-umbralisib\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  9:22 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>7&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3450632\" data-ts=\"1555334397\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/BBY\" target=\"_blank\">BBY</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3450632-analysts-back-new-best-buy-ceo\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Analysts back new Best Buy CEO</a></h4><ul> <li>The early word from analysts is positive on the elevation of Best Buy CFO (NYSE:<a href='https://seekingalpha.com/symbol/BBY' title='Best Buy Co., Inc.'>BBY</a>) Corie Barry to the company's CEO post.</li> <li>\"She is a strategic thinker who helped develop the turnaround strategy with current CEO Hubert Joly and has been at his side laying the plan for the future,\" observes Telsey Advisory Group analyst Joseph Feldman.</li><li>Bank of America Merrill Lynch also issued a positive assessment.</li> <li>Barry has been in the CFO job at Best Buy since 2016 and first joined the retailer in 1999.</li> <li>Shares of BBY are <font color=\"red\">down 0.79%</font> in premarket trading to $72.99.</li><li>Previously: <a href=\"https://seekingalpha.com/news/3450532-best-buy-appoints-new-ceo\" target=\"_blank\">Best Buy appoints new CEO</a> (April 15)</li> </ul><div class=\"tiny-share-widget\" data-id=\"3450632\" data-linked=\"Analysts back new Best Buy CEO\" data-tweet=\"$BBY - Analysts back new Best Buy CEO https://seekingalpha.com/news/3450632-analysts-back-new-best-buy-ceo?source=tweet\" data-url=\"https://seekingalpha.com/news/3450632-analysts-back-new-best-buy-ceo\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  9:19 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>5&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3450630\" data-ts=\"1555334367\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/ARWR\" target=\"_blank\">ARWR</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3450630-fda-okd-arrowhead-pharma-to-begin-late-stage-study-of-aro-aat-for-aatd\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">FDA OK&#39;d Arrowhead Pharma to begin late-stage study of ARO-AAT for AATD</a></h4><ul> <li>Arrowhead Pharmaceuticals (NASDAQ:<a href='https://seekingalpha.com/symbol/ARWR' title='Arrowhead Pharmaceuticals, Inc.'>ARWR</a>) has <a href=\"https://seekingalpha.com/pr/17476066-arrowhead-pharmaceuticals-receives-fda-clearance-begin-phase-2-3-study-aro-aat-treatment\" target=\"_blank\">received</a> FDA clearance to       proceed with an adaptive Phase 2/3 trial with the potential to serve as       a pivotal registrational study of ARO-AAT, an RNA interference (RNAi)       therapeutic being developed as a treatment for a rare genetic liver       disease associated with alpha-1 antitrypsin deficiency &#40;AATD&#41;.</li>     <li>Arrowhead intends to initiate the adaptive design, Phase 2/3 study in Q2, followed by various       international sites in Europe, pending regulatory submission and review.</li><li>The primary objectives are to evaluate safety and efficacy and       pharmacodynamic dose response, and no worsening of liver fibrosis based on Ishak score on end       of study biopsy.</li><li>Shares are up <font color=\"green\">3%</font> premarket.</li>     </ul><div class=\"tiny-share-widget\" data-id=\"3450630\" data-linked=\"FDA OK&#39;d Arrowhead Pharma to begin late-stage study of ARO-AAT for AATD\" data-tweet=\"$ARWR - FDA OK&#39;d Arrowhead Pharma to begin late-stage study of ARO-AAT for AATD https://seekingalpha.com/news/3450630-fda-okd-arrowhead-pharma-to-begin-late-stage-study-of-aro-aat-for-aatd?source=tweet\" data-url=\"https://seekingalpha.com/news/3450630-fda-okd-arrowhead-pharma-to-begin-late-stage-study-of-aro-aat-for-aatd\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  9:19 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>16&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3450624\" data-ts=\"1555333999\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/\" target=\"_blank\"></a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3450624-apha-and-rbz-among-premarket-losers\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">APHA and RBZ among premarket losers</a></h4><ul><li>Reebonz Holding (NASDAQ:<a href='https://seekingalpha.com/symbol/RBZ' title='Reebonz Holding Limited'>RBZ</a>) <font color=\"red\">-62%</font> on <a href=\"https://seekingalpha.com/news/3450590-reebonz-prices-10_8m-public-offering\" target=\"_blank\">pricing</a> public offering.</li><li>Aphria (NYSE:<a href='https://seekingalpha.com/symbol/APHA' title='Aphria Inc.'>APHA</a>) <font color=\"red\">-12%</font> on <a href=\"https://seekingalpha.com/news/3450519-aphria-misses-0_16-misses-revenue\" target=\"_blank\">Q3 earnings</a>.</li><li>ZK International Group (NASDAQ:<a href='https://seekingalpha.com/symbol/ZKIN' title='ZK International Group Co., Ltd.'>ZKIN</a>) <font color=\"red\">-11%</font>.</li><li>Clovis Oncology (NASDAQ:<a href='https://seekingalpha.com/symbol/CLVS' title='Clovis Oncology, Inc.'>CLVS</a>) <font color=\"red\">-10%</font>.</li><li>Future FinTech Group (NASDAQ:<a href='https://seekingalpha.com/symbol/FTFT' title='Future FinTech Group Inc.'>FTFT</a>) <font color=\"red\">-7%</font>.</li><li>Kitov Pharma (NASDAQ:<a href='https://seekingalpha.com/symbol/KTOV' title='Kitov Pharma Ltd'>KTOV</a>) <font color=\"red\">-6%</font>.</li><li>Castor Maritime (NASDAQ:<a href='https://seekingalpha.com/symbol/CTRM' title='Castor Maritime Inc.'>CTRM</a>) <font color=\"red\">-5%</font>.</li> </ul><div class=\"tiny-share-widget\" data-id=\"3450624\" data-linked=\"APHA and RBZ among premarket losers\" data-tweet=\"$RBZ $APHA $ZKIN - APHA and RBZ among premarket losers https://seekingalpha.com/news/3450624-apha-and-rbz-among-premarket-losers?source=tweet\" data-url=\"https://seekingalpha.com/news/3450624-apha-and-rbz-among-premarket-losers\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  9:13 AM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3450623\" data-ts=\"1555333892\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/SCHW\" target=\"_blank\">SCHW</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3450623-charles-schwab-beats-0_04-beats-on-revenue\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Charles Schwab beats by $0.04, beats on revenue</a></h4><ul><li>Charles Schwab (NYSE:<a href='https://seekingalpha.com/symbol/SCHW' title='The Charles Schwab Corporation'>SCHW</a>): Q1 GAAP EPS of $0.69 <span style=\"color:green\">beats by $0.04</span>.</li><li>Revenue of $2.72B (+13.3% Y/Y) <font color=\"green\">beats by $50M</font>.</li><li>Shares <font color=\"green\">+3.6%</font> PM.</li><li><a href=\"https://seekingalpha.com/pr/17476353-schwab-reports-record-quarterly-net-income-964-million-23-percent\">Press Release</a></li></ul><div class=\"tiny-share-widget\" data-id=\"3450623\" data-linked=\"Charles Schwab beats by $0.04, beats on revenue\" data-tweet=\"$SCHW - Charles Schwab beats by $0.04, beats on revenue https://seekingalpha.com/news/3450623-charles-schwab-beats-0_04-beats-on-revenue?source=tweet\" data-url=\"https://seekingalpha.com/news/3450623-charles-schwab-beats-0_04-beats-on-revenue\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  9:11 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>1&nbsp;<span class='comments-number'>Comment</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3450622\" data-ts=\"1555333812\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/F\" target=\"_blank\">F</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3450622-ford-shifts-to-commercial-sales-in-europe\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Ford shifts to more commercial sales in Europe</a></h4><ul> <li>Ford (NYSE:<a href='https://seekingalpha.com/symbol/F' title='Ford Motor Company'>F</a>) reports sales in Europe fell 6.2% in Q1 to 359,400 vehicles.</li> <li>Ford's total market share in the Euro 20 zone fell 40 bps to 7.6% during the quarter, although the automaker improved its commercial vehicle share to 14.5%.</li> <li>\"I'm very pleased to see that now close to half of our sales come from our commercial vehicles and SUVs. This is a trend we expect to grow as we launch more new commercial vehicles, like the Transit Custom PHEV, and SUVs, including the Explorer PHEV, in Europe during the year,\" note Ford Europe VP of Marketing Roelant de Waard.</li><li>Ford has hinted on conference calls that profitability is taking precedence over volume in Europe.</li><li>Shares of Ford are up <font color=\"green\">0.42%</font> in premarket trading.</li> </ul><div class=\"tiny-share-widget\" data-id=\"3450622\" data-linked=\"Ford shifts to more commercial sales in Europe\" data-tweet=\"$F - Ford shifts to more commercial sales in Europe https://seekingalpha.com/news/3450622-ford-shifts-to-commercial-sales-in-europe?source=tweet\" data-url=\"https://seekingalpha.com/news/3450622-ford-shifts-to-commercial-sales-in-europe\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  9:10 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>18&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3450617\" data-ts=\"1555333464\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/\" target=\"_blank\"></a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3450617-saputo-eyes-u-s-dairy-m\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Saputo eyes U.S. dairy M&amp;A</a></h4><ul> <li>Dean Foods (NYSE:<a href='https://seekingalpha.com/symbol/DF' title='Dean Foods Company'>DF</a>) is up sharply after the Globe and Mail <a href=\"https://www.theglobeandmail.com/business/article-saputo-deepens-us-operations-with-possible-acquisitions-in-dairy/\" target=\"_blank\">reported</a> over the weekend that a team from Saputo (<a href='https://seekingalpha.com/symbol/SAPIF' title='Saputo Inc.'>OTCPK:SAPIF</a>) is pouring over the company's books with an eye on a potential bid.</li> <li>Saputo is also seen as a potential bidder for Kraft Heinz's (NASDAQ:<a href='https://seekingalpha.com/symbol/KHC' title='The Kraft Heinz Company'>KHC</a>) Breakstone business.</li> <li>Shares of Dean Foods are <font color=\"green\">up 5.61%</font> in premarket action, while Kraft Heinz is <font color=\"green\">0.25% higher</font>.</li></ul><div class=\"tiny-share-widget\" data-id=\"3450617\" data-linked=\"Saputo eyes U.S. dairy M&amp;A\" data-tweet=\"$DF $SAPIF $KHC - Saputo eyes U.S. dairy M&amp;A https://seekingalpha.com/news/3450617-saputo-eyes-u-s-dairy-m?source=tweet\" data-url=\"https://seekingalpha.com/news/3450617-saputo-eyes-u-s-dairy-m\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  9:04 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>18&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3450615\" data-ts=\"1555333275\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/FCSC\" target=\"_blank\">FCSC</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3450615-fibrocell-up-51-premarket-on-castle-creek-collaboration\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Fibrocell up 51% premarket on Castle Creek collaboration</a></h4><ul><li>Nano cap Fibrocell Science (NASDAQ:<a href='https://seekingalpha.com/symbol/FCSC' title='Fibrocell Science, Inc.'>FCSC</a>) is up <font color=\"green\">51%</font> premarket on robust volume in response to its <a href=\"https://seekingalpha.com/pr/17475940-fibrocell-announces-collaboration-castle-creek-pharmaceuticals-develop-commercialize-fcxminus\" target=\"_blank\">collaboration </a>with Castle Creek Pharmaceuticals to develop and commercialize gene therapy candidate FCX-007 for recessive dystrophic epidermolysis bullosa, a rare inherited disorder characterized by fragile blistering skin.</li><li>Under the terms of the deal, Castle Creek will have an exclusive license to commercialize FCX-007 in the U.S. and will be responsible for all development and manufacturing costs up to $20M prior to the filing of a marketing application. If development spending exceeds $20M, Fibrocell will cover 30% of the excess expenses. Castle Creek will be responsible for all commercialization activities and costs while Fibrocell will maintain clinical development, regulatory interactions and manufacturing under a future supply agreement with Castle Creek.</li><li>Fibrocell will receive $7.5M upfront, $2.5M when the first patient is enrolled in a Phase 3 study, $30M when the FDA approves the marketing application and market launch is ready, up to $75M in sales-based milestones, an additional $50M if sales reach $750M and 30% of gross profits.</li><li>Fibrocell will retain sole ownership of the Rare Pediatric Disease Priority Review Voucher that it will receive on the FDA nod for FCX-007.</li><li>A Phase 3 clinical trial, DEFI-RDEB, should launch this quarter.</li></ul><div class=\"tiny-share-widget\" data-id=\"3450615\" data-linked=\"Fibrocell up 51% premarket on Castle Creek collaboration\" data-tweet=\"$FCSC - Fibrocell up 51% premarket on Castle Creek collaboration https://seekingalpha.com/news/3450615-fibrocell-up-51-premarket-on-castle-creek-collaboration?source=tweet\" data-url=\"https://seekingalpha.com/news/3450615-fibrocell-up-51-premarket-on-castle-creek-collaboration\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  9:01 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>2&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3450607\" data-ts=\"1555332451\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/EFII\" target=\"_blank\">EFII</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3450607-electronics-for-imaging-acquired-for-1_7b\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Electronics for Imaging acquired for $1.7B</a></h4><ul><li>Electronics for Imaging (NASDAQ:<a href='https://seekingalpha.com/symbol/EFII' title='Electronics for Imaging, Inc.'>EFII</a>) <a href=\"https://seekingalpha.com/pr/17476202-efi-announces-definitive-agreement-acquired-affiliate-siris-capital-group-llc-cash\" target=\"_blank\">agrees</a> to be acquired by PE firm Siris Capital Group in an all-cash transaction.</li><li>Siris will pay $37 per share, representing a 45% premium over the closing price on April 12.</li><li>EFI has a 45-day go-shop period to consider other offers. If the period expires, the Siris deal will close by Q3.</li><li>Electronics for Imaging shares were <font color=\"green\">up 25%</font> to $36.82.</li></ul><div class=\"tiny-share-widget\" data-id=\"3450607\" data-linked=\"Electronics for Imaging acquired for $1.7B\" data-tweet=\"$EFII - Electronics for Imaging acquired for $1.7B https://seekingalpha.com/news/3450607-electronics-for-imaging-acquired-for-1_7b?source=tweet\" data-url=\"https://seekingalpha.com/news/3450607-electronics-for-imaging-acquired-for-1_7b\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  8:47 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>1&nbsp;<span class='comments-number'>Comment</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3450601\" data-ts=\"1555331856\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/INSY\" target=\"_blank\">INSY</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3450601-insys-chief-motahari-out-shares-up-2-premarket\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Insys chief Motahari out; shares up 2% premarket</a></h4><ul><li>By mutual agreement, INSYS Therapeutics (NASDAQ:<a href='https://seekingalpha.com/symbol/INSY' title='INSYS Therapeutics, Inc.'>INSY</a>) President &amp; CEO Saeed Motahari has <a href=\"https://seekingalpha.com/pr/17476288-insys-therapeutics-implements-leadership-changes\" target=\"_blank\">resigned</a>. CFO Andrew Long has been promoted to CEO effective immediately.</li><li>Corporate Controller Andrece Housley has been promoted to CFO.</li><li>Dr. Venkat Goskonda has been promoted to Chief Scientific Officer.</li><li>Shares are up <font color=\"green\">2%</font> premarket on light volume.</li></ul><div class=\"tiny-share-widget\" data-id=\"3450601\" data-linked=\"Insys chief Motahari out; shares up 2% premarket\" data-tweet=\"$INSY $INSYQ - Insys chief Motahari out; shares up 2% premarket https://seekingalpha.com/news/3450601-insys-chief-motahari-out-shares-up-2-premarket?source=tweet\" data-url=\"https://seekingalpha.com/news/3450601-insys-chief-motahari-out-shares-up-2-premarket\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  8:37 AM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3450596\" data-ts=\"1555331492\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/BPTH\" target=\"_blank\">BPTH</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3450596-bio-path-up-37-premarket-on-withdrawal-of-stock-offering\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Bio-Path up 37% premarket on withdrawal of stock offering</a></h4><ul><li>Nano cap Bio-Path Holdings (NASDAQ:<a href='https://seekingalpha.com/symbol/BPTH' title='Bio-Path Holdings, Inc.'>BPTH</a>) is up <font color=\"green\">37%</font> premarket on increased volume in reaction to its withdrawal of an <a href=\"https://www.sec.gov/Archives/edgar/data/1133818/000114420418066419/tv509802_s1.htm\" target=\"_blank\">S-</a>1 filed in late December 2018 for an offering of stock and warrants.</li><li>Shares rocketed in early March after it announced positive data on prexigebersen, almost always an equity raise-provoking event. The stock peaked at $73.52 on March 7 before retracing. Shares closed at $15.65 on Friday, April 12.</li><li>On March 12, it <a href=\"https://seekingalpha.com/news/3441842-bio-path-launches-stock-offering-shares-8-percent-premarket\" target=\"_blank\">announced </a>the direct sale of ~713K common shares at $25.95 to institutional investors so its withdrawal of the registration statement may be a tactic to get them above water.</li></ul><div class=\"tiny-share-widget\" data-id=\"3450596\" data-linked=\"Bio-Path up 37% premarket on withdrawal of stock offering\" data-tweet=\"$BPTH - Bio-Path up 37% premarket on withdrawal of stock offering https://seekingalpha.com/news/3450596-bio-path-up-37-premarket-on-withdrawal-of-stock-offering?source=tweet\" data-url=\"https://seekingalpha.com/news/3450596-bio-path-up-37-premarket-on-withdrawal-of-stock-offering\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  8:31 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>1&nbsp;<span class='comments-number'>Comment</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3450594\" data-ts=\"1555331450\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/LEVI\" target=\"_blank\">LEVI</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3450594-jpmorgan-points-to-levis-brand-heritage-advantage\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">JPMorgan points to Levi&#39;s brand heritage as advantage</a></h4><ul> <li>Shares of Levi Strauss (NYSE:<a href='https://seekingalpha.com/symbol/LEVI' title='Levi Strauss & Co.'>LEVI</a>) are <font color=\"green\">up 1.34%</font> as the jeans giant lands largely favorable ratings from the analyst community.</li> <li>JPMorgan has one of the more stronger reads on Levi's in backing up its Overweight rating and $26 price target.</li> <li>\"We view the combination of a strong tenured management team led by CEO C. Bergh and brand heritage (&gt;165 years history, inventors of the 'Blue Jean') as a competitive advantage in expanding to a global lifestyle brand through 5 profitable growth buckets (Women\u2019s, Top\u2019s, International, DTC, Value brands) while growing the overall 'core' men\u2019s denim category 'at least' in line w/ the low-single-digit industry growth rate,\" reads the JP note.</li> <li>Previously: <a href=\"https://seekingalpha.com/news/3450563-analyst-coverage-levi-strauss-launches\" target=\"_blank\">Analyst coverage on Levi Strauss launches</a> (April 15)</li>  </ul><div class=\"tiny-share-widget\" data-id=\"3450594\" data-linked=\"JPMorgan points to Levi&#39;s brand heritage as advantage\" data-tweet=\"$LEVI - JPMorgan points to Levi&#39;s brand heritage as advantage https://seekingalpha.com/news/3450594-jpmorgan-points-to-levis-brand-heritage-advantage?source=tweet\" data-url=\"https://seekingalpha.com/news/3450594-jpmorgan-points-to-levis-brand-heritage-advantage\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  8:30 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>2&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3450588\" data-ts=\"1555330936\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/SPOT\" target=\"_blank\">SPOT</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3450588-spotifyminus-3_5-on-amazon-competition-billboard\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Spotify -3.5% on Amazon competition - Billboard</a></h4><ul><li>Spotify (NYSE:<a href='https://seekingalpha.com/symbol/SPOT' title='Spotify Technology S.A.'>SPOT</a>) <font color=\"red\">drops 3.5%</font> pre-market after Friday's<a href=\"https://www.billboard.com/articles/business/8506943/amazon-offer-ad-supported-music-service-exclusive\" target=\"_blank\"> Billboard report</a> that Amazon (NASDAQ:<a href='https://seekingalpha.com/symbol/AMZN' title='Amazon.com, Inc.'>AMZN</a>) plans to launch an ad-supported music streaming service.</li><li>Sources say the service would work through the Echo devices with a limited catalog of music. The offering could be available as early as this week.</li><li>Spotify is currently the only major subscription-dependent streaming company to offer a free tier with on-demand listening.</li></ul><div class=\"tiny-share-widget\" data-id=\"3450588\" data-linked=\"Spotify -3.5% on Amazon competition - Billboard\" data-tweet=\"$SPOT $AMZN - Spotify -3.5% on Amazon competition - Billboard https://seekingalpha.com/news/3450588-spotifyminus-3_5-on-amazon-competition-billboard?source=tweet\" data-url=\"https://seekingalpha.com/news/3450588-spotifyminus-3_5-on-amazon-competition-billboard\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  8:22 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>9&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3450586\" data-ts=\"1555330503\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/NOK\" target=\"_blank\">NOK</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3450586-goldman-cuts-nokia-on-competition-nokminus-3\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Goldman cuts Nokia on competition; NOK -3%</a></h4><ul><li>Nokia (NYSE:<a href='https://seekingalpha.com/symbol/NOK' title='Nokia Corporation'>NOK</a>) <font color=\"red\">drops 3.2%</font> pre-market after Goldman Sachs downgrades from Neutral to Sell citing increasing competition from Ericsson and Samsung plus NOK's projections for a slow start to the year.</li><li>The firm estimates that Nokia and Huawei each have about 23% of the global wireless networking market compared to Ericsson's 29% and Samsung's 5%.</li><li>But Samsung is ramping up its efforts including a 5G equipment partnership with Verizon, which could double the company's market share in coming years.</li></ul><div class=\"tiny-share-widget\" data-id=\"3450586\" data-linked=\"Goldman cuts Nokia on competition; NOK -3%\" data-tweet=\"$NOK - Goldman cuts Nokia on competition; NOK -3% https://seekingalpha.com/news/3450586-goldman-cuts-nokia-on-competition-nokminus-3?source=tweet\" data-url=\"https://seekingalpha.com/news/3450586-goldman-cuts-nokia-on-competition-nokminus-3\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  8:15 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>17&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3450578\" data-ts=\"1555329804\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/DBD\" target=\"_blank\">DBD</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3450578-diebold-suspends-exec-bonuses-dbdminus-5_9\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Diebold suspends exec bonuses; DBD -5.9%</a></h4><ul><li>Diebold Nixdorf's (NYSE:<a href='https://seekingalpha.com/symbol/DBD' title='Diebold Nixdorf, Incorporated'>DBD</a>) compensation committee <a href=\"https://seekingalpha.com/filing/4444136\" target=\"_blank\">suspends</a> the quarterly bonus program for named execs, effective immediately.</li><li>The company says the program was necessary to retain leaders \"during a very challenging period\" and suspends it now after accomplishing the goal of stabilizing the company and launching the DN Now initiative.</li><li>DBD shares are <font color=\"red\">down 5.9%</font> pre-market to $11.95.</li></ul><div class=\"tiny-share-widget\" data-id=\"3450578\" data-linked=\"Diebold suspends exec bonuses; DBD -5.9%\" data-tweet=\"$DBD - Diebold suspends exec bonuses; DBD -5.9% https://seekingalpha.com/news/3450578-diebold-suspends-exec-bonuses-dbdminus-5_9?source=tweet\" data-url=\"https://seekingalpha.com/news/3450578-diebold-suspends-exec-bonuses-dbdminus-5_9\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  8:03 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>3&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3450567\" data-ts=\"1555329517\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/AKAO\" target=\"_blank\">AKAO</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3450567-achaogen-files-for-bankruptcy-protection\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Achaogen files for bankruptcy protection</a></h4><ul><li>Longs in nano cap Achaogen (NASDAQ:<a href='https://seekingalpha.com/symbol/AKAO' title='Achaogen, Inc.'>AKAO</a>) are facing a near-total wipeout this morning on the news that it has filed for Chapter 11 bankruptcy protection.</li><li>Trading is currently suspended.</li><li><strong>Update</strong>: Shares are down <font color=\"red\">57%</font> on resumption of trading.</li></ul><div class=\"tiny-share-widget\" data-id=\"3450567\" data-linked=\"Achaogen files for bankruptcy protection\" data-tweet=\"$AKAO - Achaogen files for bankruptcy protection https://seekingalpha.com/news/3450567-achaogen-files-for-bankruptcy-protection?source=tweet\" data-url=\"https://seekingalpha.com/news/3450567-achaogen-files-for-bankruptcy-protection\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  7:58 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>68&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3450563\" data-ts=\"1555328616\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/LEVI\" target=\"_blank\">LEVI</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3450563-analyst-coverage-on-levi-strauss-launches\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Analyst coverage on Levi Strauss launches</a></h4><ul> <li>Levi Strauss (NYSE:<a href='https://seekingalpha.com/symbol/LEVI' title='Levi Strauss & Co.'>LEVI</a>) is on watch after the first batch of ratings from investment firms are doled out.</li> <li>Positive ratings are in from Citi (Buy), Guggenheim (Buy), Telsey (Outperform) and JPMorgan (Overweight).</li> <li>Starting off Levi's with a more cautious stance are Goldman Sachs (Neutral), Morgan Stanley (Equal-weight) and Bank of America Merrill Lynch (Neutral).</li> <li>\"We think the potential for higher EPS can support the multiple, but meaningful expansion is difficult with shares already at a substantial premium to other apparel vendors,\" reads the BAML first pass at Levi's.</li> <li>Shares of Levi's are <font color=\"green\">up 2.09%</font> to $22.92 vs. the IPO pricing level of $17 and post-IPO high of $24.19.</li> </ul><div class=\"tiny-share-widget\" data-id=\"3450563\" data-linked=\"Analyst coverage on Levi Strauss launches\" data-tweet=\"$LEVI - Analyst coverage on Levi Strauss launches https://seekingalpha.com/news/3450563-analyst-coverage-on-levi-strauss-launches?source=tweet\" data-url=\"https://seekingalpha.com/news/3450563-analyst-coverage-on-levi-strauss-launches\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  7:43 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>4&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3450552\" data-ts=\"1555327845\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/AXSM\" target=\"_blank\">AXSM</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3450552-axsomes-axsminus-05-meets-primary-endpoint-in-mid-stage-trial-in-smoking-cessation\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Axsome&#39;s AXS-05 meets primary endpoint in mid-stage trial in smoking cessation</a></h4><ul> <li>Axsome Therapeutics (NASDAQ:<a href='https://seekingalpha.com/symbol/AXSM' title='Axsome Therapeutics, Inc.'>AXSM</a>) <a href=\"https://seekingalpha.com/pr/17475936-axsome-therapeutics-announces-axsminus-05-achieves-primary-endpoint-phase-2-trial-smoking\" target=\"_blank\">reports</a> topline analysis of the Phase 2 trial of <a href=\"https://axsome.com/axs-pipeline/about-axs-05/\" target=\"_blank\">AXS-05</a> for smoking cessation treatment.</li><li>AXS-05 met the prespecified primary endpoint and significantly reduced daily smoking as compared to the active comparator bupropion.</li><li>The trial was conducted at the Duke Center for Smoking Cessation under a research collaboration between Axsome and Duke University.</li><li>In study, 58 adult smokers were treated either with AXS-05 (45 mg dextromethorphan/105 mg bupropion), or the active comparator bupropion (105 mg), twice daily, and assessed over a 3-week period.</li><li>Shares are up <font color=\"green\">3%</font> premarket.</li>        </ul><div class=\"tiny-share-widget\" data-id=\"3450552\" data-linked=\"Axsome&#39;s AXS-05 meets primary endpoint in mid-stage trial in smoking cessation\" data-tweet=\"$AXSM - Axsome&#39;s AXS-05 meets primary endpoint in mid-stage trial in smoking cessation https://seekingalpha.com/news/3450552-axsomes-axsminus-05-meets-primary-endpoint-in-mid-stage-trial-in-smoking-cessation?source=tweet\" data-url=\"https://seekingalpha.com/news/3450552-axsomes-axsminus-05-meets-primary-endpoint-in-mid-stage-trial-in-smoking-cessation\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  7:30 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>5&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3450550\" data-ts=\"1555327597\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/FIVE\" target=\"_blank\">FIVE</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3450550-five-belowplus-2-after-baml-sees-rally-extending\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Five Below +2% after BAML sees rally extending</a></h4><ul> <li>Bank of America Merrill Lynch initiates coverage on Five Below (NASDAQ:<a href='https://seekingalpha.com/symbol/FIVE' title='Five Below, Inc.'>FIVE</a>) with a Buy rating and price objective of $150.</li> <li>\"We believe FIVE will continue to beat and raise its EPS leading to further stock price appreciation,\" writes BAML analyst David Buckley.</li> <li>\"Management continues to find ways to drive outsized comp and earnings growth and we expect that to continue. We believe FIVE\u2019s strategy of continuously reinvesting in its products to improve its offering will to drive low to mid-single digit comp growth through 2021,\" he adds.</li> <li>BAML expects FY19 EPS of $3.06 out of Five Below and FY20 EPS of $3.84.</li> <li>Shares of Five Below are <font color=\"green\">1.54% higher</font> in premarket trading to $137.00.</li>  </ul><div class=\"tiny-share-widget\" data-id=\"3450550\" data-linked=\"Five Below +2% after BAML sees rally extending\" data-tweet=\"$FIVE - Five Below +2% after BAML sees rally extending https://seekingalpha.com/news/3450550-five-belowplus-2-after-baml-sees-rally-extending?source=tweet\" data-url=\"https://seekingalpha.com/news/3450550-five-belowplus-2-after-baml-sees-rally-extending\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  7:26 AM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3450544\" data-ts=\"1555327217\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/\" target=\"_blank\"></a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3450544-waste-management-in-5b-deal-for-advanced-disposal\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Waste Management in $5B deal for Advanced Disposal</a></h4><ul><li>At $33.15 per share in cash, <a href=\"https://investors.wm.com/news-releases/news-release-details/waste-management-acquire-advanced-disposal-49-billion-adding\" target=\"_blank\">the purchase by</a> Waste Management (NYSE:<a href='https://seekingalpha.com/symbol/WM' title='Waste Management, Inc.'>WM</a>) assigns an enterprise value of $4.9B to Advanced Disposal (NYSE:<a href='https://seekingalpha.com/symbol/ADSW' title='Advanced Disposal Services, Inc.'>ADSW</a>), a <font color=\"green\">22.1% premium</font> to Friday's close.</li><li>The deal is seen being immediately accretive to WM's earnings and cash flow, with more than $100M of annual cost savings expected.</li><li>The acquisition is expected to close by the end of Q1 2020.</li><li>ADSW <font color=\"green\">+20.7%</font> to $32.75, WM <font color=\"green\">+2.2% </font>premarket</li></ul><div class=\"tiny-share-widget\" data-id=\"3450544\" data-linked=\"Waste Management in $5B deal for Advanced Disposal\" data-tweet=\"$WM $ADSW - Waste Management in $5B deal for Advanced Disposal https://seekingalpha.com/news/3450544-waste-management-in-5b-deal-for-advanced-disposal?source=tweet\" data-url=\"https://seekingalpha.com/news/3450544-waste-management-in-5b-deal-for-advanced-disposal\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  7:20 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>12&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3450540\" data-ts=\"1555327113\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/ADNT\" target=\"_blank\">ADNT</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3450540-adientminus-3-after-light-fq2-revenue-guide\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Adient -3% after light FQ2 revenue guide</a></h4><ul> <li>Adient (NYSE:<a href='https://seekingalpha.com/symbol/ADNT' title='Adient plc'>ADNT</a>) announces preliminary results for <a href=\"https://seekingalpha.com/pr/17476024-adient-announces-preliminary-q2-fiscal-2019-results-realigns-reportable-segments\" target=\"_blank\">FQ2</a>.</li> <li>The company says revenue is expected to be reported at ~$4.2B vs. $4.26B consensus, adjusted EBITDA is expected to be between $185M and $195M and free cash flow is expected to be between $45M and $60M.</li> <li>\"Adient's preliminary Q2 results demonstrate that the actions taken to improve the company's operational and financial performance are taking hold,\" says CEO Doug Del Grosso.</li> <li>In addition to the earnings announcement, Adient also discloses that it reorganized certain elements of its management structure which resulted in a realignment of its reportable segments (Americas, EMEA, Asia Pacific).  The company expects the organizational changes to result in a flatter organization with three fully integrated regions.</li><li>Shares of Adient are <font color=\"red\">down 3.33%</font> in premarket trading.</li> </ul><div class=\"tiny-share-widget\" data-id=\"3450540\" data-linked=\"Adient -3% after light FQ2 revenue guide\" data-tweet=\"$ADNT - Adient -3% after light FQ2 revenue guide https://seekingalpha.com/news/3450540-adientminus-3-after-light-fq2-revenue-guide?source=tweet\" data-url=\"https://seekingalpha.com/news/3450540-adientminus-3-after-light-fq2-revenue-guide\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  7:18 AM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3450536\" data-ts=\"1555326942\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/AUY\" target=\"_blank\">AUY</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3450536-yamana-gold-to-sell-chapada-mine-to-lundin-for-1b-plus-raises-dividend\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Yamana Gold to sell Chapada mine to Lundin for $1B-plus, raises dividend</a></h4><ul><li>In a deal Yamana Gold (NYSE:<a href='https://seekingalpha.com/symbol/AUY' title='Yamana Gold Inc.'>AUY</a>) says will improve its balance sheet and shareholder return, the miner <a href=\"https://www.globenewswire.com/news-release/2019/04/15/1803837/0/en/Yamana-Gold-Announces-Agreement-to-Sell-the-Chapada-Mine-for-Total-Consideration-Over-1-0-Billion-Delivering-Significant-Improvements-to-the-Balance-Sheet-and-Shareholder-Returns.html\" target=\"_blank\">agrees to sell</a> its wholly-owned Chapada copper mine in Brazil to Lundin Mining (<a href='https://seekingalpha.com/symbol/LUNMF' title='Lundin Mining Corporation'>OTCPK:LUNMF</a>) for more than $1B.</li><li>AUY says it also will increase its annual dividend to $0.04/share, effective immediately.</li><li>AUY says it will receive $800M cash from Lundin at closing, additional consideration of up to $125M based on the price of gold, a $100M payment contingent on the development of a pyrite circuit to optimize the operation, and a royalty on the adjacent Suruca gold project.</li><li>Shares <font color=\"green\">+5.4%</font> pre-market.</li></ul><div class=\"tiny-share-widget\" data-id=\"3450536\" data-linked=\"Yamana Gold to sell Chapada mine to Lundin for $1B-plus, raises dividend\" data-tweet=\"$AUY $LUNMF - Yamana Gold to sell Chapada mine to Lundin for $1B-plus, raises dividend https://seekingalpha.com/news/3450536-yamana-gold-to-sell-chapada-mine-to-lundin-for-1b-plus-raises-dividend?source=tweet\" data-url=\"https://seekingalpha.com/news/3450536-yamana-gold-to-sell-chapada-mine-to-lundin-for-1b-plus-raises-dividend\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  7:15 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>43&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3450531\" data-ts=\"1555326540\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/WDC\" target=\"_blank\">WDC</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3450531-longbowplus-1_6-longbow-leaves-sidelines\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Longbow +1.6% as Longbow leaves sidelines</a></h4><ul><li>Longbow Research upgrades Western Digital (NASDAQ:<a href='https://seekingalpha.com/symbol/WDC' title='Western Digital Corporation'>WDC</a>) from Neutral to Buy with a $65 price target, implying a 25% upside.</li><li>Earlier this month, Longbow <a href=\"https://seekingalpha.com/news/3447256-weak-dram-cause-micron-struggles-longbow\" target=\"_blank\">reiterated</a> Neutral ratings on WDC and Micron citing potential continuing struggles due to weak DRAM contract prices, which were expected to hit bottom in H2. The firm thought NAND was faring better and hit bottom in March.</li><li>WDC shares are <font color=\"green\">up 1.6%</font> pre-market to $52.66.</li><li>Update with more info from the upgrade:</li><li>Longbow cites the NAND bottoming and \"a line of sight to cyclical recovery\" with the industry's capex/production likely to be further rationalized with profitability under pressure.</li><li>The firm also thinks the H2 hard drive revenue/gross margin recovery isn't fully contemplated by the Street.</li></ul><div class=\"tiny-share-widget\" data-id=\"3450531\" data-linked=\"Longbow +1.6% as Longbow leaves sidelines\" data-tweet=\"$WDC - Longbow +1.6% as Longbow leaves sidelines https://seekingalpha.com/news/3450531-longbowplus-1_6-longbow-leaves-sidelines?source=tweet\" data-url=\"https://seekingalpha.com/news/3450531-longbowplus-1_6-longbow-leaves-sidelines\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  7:09 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>3&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li>","count":75,"message":null,"success":true,"today":{"start":1577077200,"end":1577163599,"str":"Monday, December 23, 2019"},"yesterday":{"start":1576990800,"end":1577077199}}